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Abstract 
Human telomerase, a ribonucleoprotein complex consisting of a catalytic subunit 
(hTERT) and a RNA template component (TERC), prevents telomere attrition in human 
embryonic stem cells (hESCs) providing these cells with prolonged replicative capacity. 
Interestingly, hTERT has several alternatively spliced isoforms, most of which are 
catalytically inactive. One alternative splicing event involving a complete loss of exons 7 and 
8 results in a catalytically inactive isoform called β-hTERT. The β-hTERT is highly 
expressed in certain cancer types and hESCs. Full-length hTERT (FL-hTERT) is known to 
translocate from nuclei to mitochondria when cells are exposed to either chronic (oxygen 
tension) or acute (hydrogen peroxide) oxidative stress. In this study, I examined the 
alternative splicing of endogenous hTERT transcript in hESC, intra-cellular localization of 
FL-hTERT and β-hTERT in hESCs, and the effect of overexpressing recombinant hTERT on 
hESC mitochondria. Human ESCs (HES2 line) were cultured under 2% oxygen and 3xFLAG 
tagged FL-hTERT and β-hTERT were induced by doxycycline prior to 100μM H2O2 
treatment. My results demonstrate that overexpression of transgenic FL-hTERT resulted in a 
significant increase in endogenous β-hTERT transcript level. Additionally, doxycycline and 
H2O2 altered the splicing pattern of hTERT in favor of β-hTERT. I demonstrate that not only 
the full-length- but also β-hTERT can bind TERC, and that β-hTERT overexpression inhibits 
telomerase activity in vitro. However, I failed to observe the mitochondrial localization of 
recombinant FL-hTERT or β-hTERT. Lastly, my results demonstrate the pro-apoptotic role 
of β-hTERT and the pro-survival effect of FL-hTERT under H2O2-induced oxidative stress.  
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iv 
 
Acknowledgements 
 I would like to start by thanking Dr. Dean H. Betts for giving me both financial and 
spiritual support over three and half years of my master’s degree. He was always there to 
give me good pat on the back in times of discouragement, and great scientific insight to help 
me move forward with the research. I was very fortunate to have him as my supervisor. 
Without him, I could not have made this far. Once again, I thank him for the unconditional 
support and guidance he has given me throughout my study at Western University. 
 I owe greatly to our lab’s post-doctoral researcher Dr. Jonathan H. Teichroeb for 
many things. His expertise in cell cloning and telomerase was the greatest intellectual asset I 
was lucky to have access to. He never hesitated to lend me a hand with new or difficult 
experimental tasks, and graciously let me use his model human embryonic cell lines. Thank 
you, Jonathan, for your great mentorship and friendship.  
 When I started here, I knew very little about culturing cells, not to mention how to 
culture human embryonic cells. But I now feel very confident with it, thanks to Courtney 
Brooks our stem cell technician. Professional at work, yet very friendly and attentive as a 
friend, Courtney is the greatest member of the lab and friend. Thank you for your precious 
contribution to every aspect of my research.  
 Through the struggles of my master’s degree, I have come to appreciate how great 
and precious my lab mates are to me. I thank all my lab mates not only for the technical and 
scientific advice, but also for the laughter and heart-felt chatter we have had together. I would 
like to say special thanks to Ian Tobias and Shelby Oak for helping with cell count analysis. 
Thank you, all members of DDT lab. 
v 
 
Table of Contents 
Certificate of examination                                                                                                         ii 
Abstract                                                                                                                                     iii 
Acknowledgements                                                                                                                   iv 
Table of Contents                                                                                                                       v 
List of Tables                                                                                                                             x 
List of Figures                                                                                                                           xi 
List of Appendices                                                                                                                  xiv 
List of Abbreviations                                                                                                               xv 
Chapter 1: Introduction and Literature Review                                                                         1 
1.1 Human Embryonic Stem Cells                                                                                1                                       
1.1.1 Signaling pathways in hESC                                                                 2                                       
1.1.2 The role of oxygen tension in embryonic stem cells                             4                                       
1.1.3 Energy metabolism of pluripotent stem cells                                        5 
1.1.4 Telomerase and telomere in human embryonic Stem cells                   7 
1.2 Human Telomerase Catalytic Subunit hTERT                                                        8 
1.2.1 Canonical function of hTERT                                                               8 
1.2.2 Alternative splicing of hTERT                                                             10 
1.2.3 Transcriptional regulation of hTERT                                                   14 
1.2.4 Post-translational regulation of hTERT                                               16 
1.3 Non-canonical functions of Human Telomerase Catalytic Subunit hTERT         20 
1.3.1 Non-canonical functions of hTERT in Wnt/β-catenin pathway          20 
1.3.2 Non-canonical functions of hTERT in NF-kB pathway                      21 
vi 
 
1.3.3 Non-canonical function of hTERT as RNA-dependant RNA             22 
polymerase (RdRP) 
1.3.4 Mitochondrial functions of hTERT                                         24 
1.4 Rationale                          25             
Chapter 2: Materials and Methods                        28 
2.1 Cell culture                          28 
2.1.1 Mouse embryonic fibroblasts feeder cells                     28 
2.1.2 Human embryonic stem cell line HES2                   28 
2.1.3 Establishment of monoclonal transgenic HES2 lines         29 
2.1.4 Cell treatment scheme                        30 
2.2 PCR protocols                         31 
2.2.1 General real-time quantitative PCR protocol        31 
2.2.2 Detection and quantitation of hTERT isoforms by hydrolysis-probe 
assisted PCR             31 
2.2.3 RNA-immunoprecipitation and PCR-assisted detection of TERC     34 
2.2.4 PCR amplification of mitochondrial DNA for mitochondria DNA copy 
number             34 
2.3 Telomerase activity assay                      35 
2.4 Immunodetection of 3xFLAG-hTERT isoforms                  36 
2.4.1 Western blot analysis             36 
2.4.2 Immunocytochemistry            37 
2.4.3 Cell count analysis for intra-nuclear localization of 3xFLAG-hTERT 
isoforms         38 
2.5 Flowcytometry                       40 
2.5.1 Mitochondria membrane potential          40 
2.5.2 Detection of apoptosis            41 
2.6 Statistical Analyses                                                                  42 
vii 
 
Chapter 3: Results                                 43 
3.1 Basic cell characterization of human embryonic stem cells                43 
3.1.1 Characterization of pluripotency markers in human embryonic stem 
cells                       43 
3.1.2 Characterization of hTERT isoforms in human embryonic stem cells43 
3.2 Characterization of 3xFLAG-hTERT transgenic clones          47 
3.2.1 Characterization of 3xFLAG-hTERT transgene expression level in 
transgenic hESC clones        47 
3.2.2 Characterization of Pluripotency in HES2 B6 and HES2 FL12 hTERT 
cell lines          48 
3.3 Characterization of recombinant hTERT in HES2 B6 and HES2 FL12               52 
3.3.1 Endogenous TERC-binding of 3xFLAG-β-hTERT and 3xFLAG-FL-
hTERT subunits         52 
3.3.2 Endogenous RMRP-binding of 3xFLAG-β-hTERT and 3xFLAG-FL-
hTERT subunits                      52 
3.3.3 Telomerase activity in HES2 B6 and HES2 FL12 hESCs               52 
3.3.4 Re-visiting DOX-induction of 3xFLAG-hTERT transcription in HES2 
clones           53 
3.4 3xFLAG-hTERT localization under H2O2-induced oxidative stress    58 
3.4.1 Sub-cellular Western Blot Analysis of 3xFLAG-FL-hTERT and 
3xFLAG-β-hTERT expressing hESC lines      58 
3.4.2 Immunocytochemistry and Image analysis of 3xFLAG-FL-hTERT and 
3xFLAG-β-hTERT localization in hESCs        58 
3.5 The effect of overexpressed 3xFLAG-hTERT on Mitochondrial Function   64 
3.5.1 The effect of DOX-induced 3xFLAG-hTERT on mitochondria 
membrane potential                    64 
viii 
 
3.5.2 The effect of DOX-induced 3xFLAG-hTERT on mitochondrial DNA 
copy number          64 
3.5.3 The effect of DOX-induced 3xFLAG-hTERT on mitochondria 
biogenesis and function        65 
3.6 The effect of doxycycline-induced 3xFLAG-hTERT on cell survival in HES2 
lines under H2O2-induced oxidative stress                 71 
Chapter 4: Discussion           76 
4.1 Pluripotency and alternative splicing of endogenous hTERT in hESC            77 
4.2 Transgenic HES2 line B6 and FL12 remain pluripotent following doxycycline and 
H2O2 treatment          82 
4.3 3xFLAG-hTERT in HES2 B6 and HES2 FL12 bind TERC and RMRP   86 
4.4 The effect of doxycycline on survival and cell death of HES2 lines under H2O2-
induced oxidative stress         88 
4.5 The intra-cellular localization of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT in 
hESCs treated with H2O2-induced oxidative stress                                       91 
4.6 Investigation of the effect of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT on 
mitochondria function in hESCs         94 
4.7 The effect of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT on cell survival of HES2 
lines under H2O2-induced oxidative stress                                                               97 
4.8 Concluding remark and proposed future studies                           100 
Chapter 5: Reference          102 
Appendix: Supplemental Figures and Tables                  124 
A1: Table 2.1 List of PCR primers                   124 
A2: Table 2.2 List of antibodies and dyes                 127 
ix 
 
A3: Fig. 3.1 The amount of 3xFLAG-hTERT in the respective HES2 clones after 6-   
hours and 12- hours post doxycycline induction                 128 
A4: Fig. 3.2 H2O2-induced oxidative stress and its effect on the cellular localization of 
3xFLAG-hTERT          129 
A5: Fig. 3.3: The effect oxygen tension on the intra-cellular localization of 3xFLAG-FL-
hTERT in hESC           130 
Curriculum Vitae                           131 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Tables 
Table Description Page 
A1: 2.1 List of PCR primers 124 
A2: 2.2 List of antibodies and dyes 127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
List of Figures 
Figure Description Page 
1.1 mRNA and protein structure of the major hTERT isoforms 13 
1.2 Post-translational modification and function of hTERT 19 
2.1 Transgene structure and TaqMan qPCR probe-/primer-binding sites 33 
2.2 Representative confocal microscopy images of ‘uniform’ and 
‘peripheral’ distribution of 3xFLAG-FL-hTERT within nuclei 
39 
3.1 HES2 is a hESC cell line that expresses various markers of pluripotency 
and different proportions of endogenous telomerase reverse transcriptase 
(TERT) isoform transcripts 
45 
3.2 Endogenous β-hTERT transcript is ubiquitously present at high levels in 
human embryonic cells grown under low oxygen tension conditions, with 
and without H2O2 and/or doxycycline (DOX) treatments 
46 
3.3 RT-qPCR and Western blot analysis of doxycycline-induced expression 
of 3xFLAG-hTERT isoforms in HES2 clones over 3-day time course 
49 
3.4 H2O2 and DOX treatments do not affect pluripotency marker expression 
in the 3xFLAG-β-hTERT transgenic HES2 B6 line 
50 
3.5 H2O2 and DOX treatments do not affect pluripotency of the 3xFLAG-
FL-hTERT transgenic HES2 FL12 lines 
51 
3.6 Doxycycline-induced transgenic telomerase proteins (3xFLAG-β-hTERT 
and 3xFLAG-FL-hTERT) bind to the telomerase RNA component  
54 
3.7 Enrichment of RNA component of mitochondrial RNA processing 
endoribonuclease (RMRP by doxycycline-induced transgenic telomerase 
proteins (3xFLAG-β-hTERT and 3xFLAG-FL-hTERT) 
55 
xii 
 
 
Figure Description Page 
3.8 Altered telomerase activity levels in doxycycline (DOX)-induced 
transgenic telomerase proteins (3xFLAG-hTERT) in hESCs 
56 
3.9 DOX-induction of 3xFLAG-hTERT isoforms results in a simultaneous 
increase in the amount of other hTERT transcript variants containing β-
deletion 
57 
3.10 H2O2-induced Oxidative stress and its effect on the cellular localization 
of 3xFLAG-β-hTERT 
60 
3.11 H2O2-induced Oxidative stress and its effect on the cellular localization 
of 3xFLAG-FL-hTERT 
61 
3.12 H2O2-induced effect on the intra-cellular localization of 3xFLAG-β-
hTERT and 3xFLAG-FL-hTERT in hESCs 
62 
3.13 Microscopic analysis of intra-nuclear localization of 3xFLAG-β-hTERT 
and 3xFLAG-FL-hTERT under H2O2-induced oxidative stress 
63 
3.14 Mitochondrial membrane potential (MMP) gating strategy and controls 
for flow cytometry experiment with JC-1 dye measurements 
66 
3.15 3xFLAG-β-hTERT and 3xFLAG-Full-Length-hTERT do not affect 
mitochondrial membrane potential (MMP) in hESCs 
67 
3.16 Doxycycline affects mitochondria copy number in hESCs 68 
3.17 The effect of 3xFLAG-β-hTERT and 3xFLAG-Full-Length-hTERT 
overexpression on mitochondria biogenesis regulator gene expression 
69 
 
 
xiii 
 
Figure Description Page 
3.18 DOX-induced 3xFLAG-β-hTERT and 3xFLAG-Full-Length-hTERT 
overexpression does not affect UCP2 and SOD2 transcript abundance 
levels 
70 
3.19 Representative plots showing stain controls and gating strategies for 
flowcytometry experiment with 7-AAD and Annexin V for measuring 
cell death upon H2O2 treatment 
72 
3.20 Effect of DOX-induced 3xFLAG-β-hTERT and 3xFLAG-Full-Length-
hTERT on cell viability in HES2 under H2O2-induced cell stress 
73 
3.21 Effect of DOX-induced 3xFLAG-β-hTERT and 3xFLAG-Full-Length-
hTERT on apoptosis in HES2 under H2O2-induced cell stress 
74 
3.22 Effect of DOX-induced 3xFLAG-β-hTERT and 3xFLAG-Full-Length-
hTERT on cell death in HES2 under H2O2-induced cell stress 
75 
A3 3.1 The amount of 3xFLAG-hTERT in the respective HES2 clones after 6-
hours and 12- hours post doxycycline induction 
128 
A4 3.2 H2O2-induced oxidative stress and its effect on the cellular localization of 
3xFLAG-hTERT 
129 
A5 3.3 The effect oxygen tension on the intra-cellular localization of 3xFLAG-β-
hTERT and 3xFLAG-FL-hTERT in hESCs 
130 
 
 
 
 
xiv 
 
List of Appendices 
Appendix Description Page 
A1 List of PCR primers 124 
A2 List of antibodies and dyes 127 
A3 The amount of 3xFLAG-hTERT in the respective HES2 clones after 6-
hours and 12- hours post doxycycline induction 
128 
A4 H2O2-induced oxidative stress and its effect on the cellular localization 
of 3xFLAG-hTERT 
129 
A5 The effect oxygen tension on the intra-cellular localization of 
3xFLAG-β-hTERT and 3xFLAG-FL-hTERT in hESCs 
130 
 
 
 
 
 
 
 
 
 
xv 
 
List of Abbreviations 
ALT Alternative lengthening of telomere 
APC Adenomatosis polyposis coli 
BIO 6-bromoindirubin-3-oxime 
BRG1  Brahma-related gene 1 
BSA Bovine serum albumin 
Abl Abelson murine leukemia viral oncogene homolog 1 
CHIP C terminus of HSC70-Interacting Protein 
CRM1 Chromosomal maintenance 1 
Ct Cycle threshold  
DHS DNAse I hypersensitive site 
DMEM Dulbecco's modified eagle medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DSB Double-stranded break 
ESC Embryonic stem cell 
ESE Exonic splicing enhancer 
ESS Exonic splicing silencer 
ETC Electron transport chain 
FBS Fetal bovine serum 
FL Full length 
GSK3β Glycogen synthase kinase 3 beta 
hESC Human embryonic stem cell 
xvi 
 
HIF1A Hypoxia-inducible factor 1 alpha 
HIF2A Hypoxia-inducible factor 2 alpha 
HK2 Hexokinase 2 
hnRNP Heterogeneous ribonucleoprotein 
hPSC Human pluripotent stem cell 
HSP90 Heat shock protein 90 
iPSC Induced pluripotent stem cell 
ISE Intronic splicing enhancer 
ISS Intronic splicing siliencer 
LRP Lipoprotein receptor-related protein 
MEF Mouse embryonic fibroblast 
MFN1/2 Mitofusin 1/2 
MKRN1 Makorin ring finger protein 1 
MMP  Mitochondria membrane potential 
mtDNA Mitochondrial DNA 
mTHF L-methyl-tetrahydrofolate 
mTOR Mechanistic target of rapamycin 
NLS Nuclear localization signal 
NMD Nonsense mediated decay 
NP-40 Nonidet-P40 
NS Nucleostemin 
ORF Open reading frame 
OXPHOS Oxidative phosphorylation 
PBS Phosphate buffered saline 
xvii 
 
PCR Polymerase chain reaction 
PDH Pyruvate dehydrogenase 
PFK Phophofructokinase 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PKC Protein kinase C 
Plk1 Polo-like kinase 1 
PP2A Protein phosphatase 2A 
PSC Pluripotent stem cell 
PTB Polypyrimidine tract binding protein 
PTDC Pyrrolidinethiocarbamate 
RdRP RNA-dependant RNA Polymerase 
RISC RNA-induced silencing complex 
RMRP RNA component of the mitochondrial RNA-processing endoribonuclease 
RNA Ribonucleic acid 
RNP Ribonucleoprotein 
ROS Reactive oxygen species 
RT Reverse transcriptase 
S1P Sphingosine-1-phosphate 
siRNA Small-interfering RNAs 
snRNP Small nucleolar ribonucleoprotein 
SSEA Stage-specific embryonic antigen 
TBE Tris/Borate/EDTA 
TCA Tricarboxylic acid 
TCF/LEF T-cell factor/lymphoid enhancer factor 
xviii 
 
TDH Threonine dehydrogenase 
TEN Telomerase essential N-terminal 
TERC Telomerase RNA component 
TERT Telomerase reverse transcriptase 
THF Tetrahydrofolate 
TNF Tumor necrosis factor 
UCP2 Uncoupling protein 2 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
Chapter 1: Introduction and Literature Review 
1.1 Human Embryonic Stem Cells 
 In 1998, Jamie Thomson isolated human embryonic stem cells (hESCs) from the 
inner cell mass of a day 5-6 blastocyst [1]. Two defining characteristics of hESCs that define 
their therapeutic potential are their indefinite self-renewal capability and their ability to 
differentiate into cell types that comprise all three germ layers (endoderm, mesoderm, 
ectoderm) of a developing embryo including the germ cell lineage. Morphologically, hESCs 
grow in tight, spherical colonies when cultured on plastic dishes. Their cell size is small with 
very large nuclei compared to a small cytoplasmic space. hESCs are positive for various 
pluripotency markers such as alkaline phosphatase activity, pluripotency transcription factors 
(such as OCT4, NANOG, SOX2), glycolipids (stage specific embryonic antigens SSEA-3 
and SSEA-4), and keratan sulfate antigens (Tra-1-60 and Tra-1-81) [2]. For their pluripotent 
nature and its stark resemblance to other immortal cell types, hESCs stand in the centre of 
research for human development, aging, cancer, and regenerative medicine. To address the 
ethical and technical difficulties associated with the derivation of hESCs, it was demonstrated 
that pluripotency could be induced directly from differentiated somatic cells of mice [3] and 
humans [4,5]. Despite many studies confirming the differentiation competency of these so 
called induced-pluripotent stem cells (iPSCs), iPSCs vary significantly in their self-renewal 
capacity due, in part, to their heterogeneity in telomerase activity levels and/or telomere 
lengths [6,7]. Human ESCs, like other PSCs, ubiquitously express high levels of telomerase 
activity [8]. In support of this, hESCs have a unusually long S phase of the cell cycle where 
telomere elongation by telomerase takes place [9] and have distinctive cell properties such as 
heavy reliance on glycolytic metabolism [10-13], and elevated DNA-repair/defenses [14-16]. 
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1.1.1 Signaling pathways in hESCs 
Typical PSC media for feeder-free growth conditions includes factors such as insulin-
like growth factor (IGF) a strong stimulant for the canonical phosphatidylinositol-3 kinase 
(PI3K) signaling pathway [17,18]. PI3K/AKT signaling is crucial for maintenance of hESC 
pluripotency [19, 20].  PI3K/AKT is a signaling pathway best known for its regulatory role in 
cell cycle regulation. Its function is especially important in actively proliferating cell types 
such as cancer cells and hESCs. A microarray experiment by Armstrong et al. revealed a 
highly active PI3K/AKT signal-transduction in undifferentiated ESCs [18].  Inhibition of 
PI3K/AKT in hESCs resulted in a significant loss of core pluripotency marker (OCT4, 
NANOG, SOX2) expression, confirming the requirement of PI3K signaling in the 
maintenance of hESC pluripotency. When activated, AKT1 initiates a signaling cascade by 
activating mTOR and by inhibiting GSK3[19]. Inhibition of PI3K/AKT signaling by small 
molecules such as LY294002 or by removal of PI3K activators leads to an eventual loss of 
pluripotency in hPSCs [19, 20, 23]. The mechanisms of how PI3K controls the pluripotent 
state in hPSCs are unclear. It is speculated that PI3K/AKT regulates protein synthesis 
through mTOR, thereby regulating the protein synthesis of core factors of the pluripotency 
network [21]. Inhibition of mTOR by rapamycin results in similar effects to that of AKT 
inhibition, triggering spontaneous hPSC differentiation [19, 24]. GSK3 inhibition by AKT 
signaling may also contribute to PSC maintenance through Wnt/β-catenin-mediated 
expression of c-myc, a key regulator of PSC maintenance [25, 26]. This mechanism could 
also apply in hPSCs, but has not been evaluated fully. 
The role of canonical Wnt/β-catenin pathway in human ESCs is a controversial one. 
At first, the activation of Wnt/β-catenin pathway via either Wnt3A (ligand of Wnt-receptor) 
or GSK3 inhibitor 6-bromoindirubin-3′-oxime (BIO) was shown to have a significant role in 
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the self-renewal of hESCs (H1 and H9 cell line) under feeder-free conditions [27-29]. In 
presence of BIO, Wnt-signaling sustained the expression of Oct-3/4, Rex1, and Nanog. The 
effect was reversed when BIO was withdrawn from the culture, resulting in spontaneous 
multi-differentiation of hESCs. However, the consequences of blocking GSK3 are not limited 
to Wnt/β-catenin pathway, and can affect many other pathways through mTOR 
stabilization/cross-talk between signaling pathways. For instance, inhibition of GSK3 via 
BIO results in increased phosphorylated Smad2/3 in hESCs, a downstream Nodal signaling 
pathway characteristic of the undifferentiated state of hESCs [26].  In support of this view, 
contradicting results emerged afterwards, demonstrating that Wnt/β-catenin activation by 
Wnt3A/BIO does not support the self-renewal of hPSCs in long term cultures [30-32]. 
Moreover, their functional reporter assay showed that β-catenin-mediated transcription 
activity was nearly absent in undifferentiated hESCs (H1 and H9 cell lines). Further studies 
with a chimeric (estrogen-receptor tagged) β-catenin model showed that 4-
hydroxytamoxifen-induced activation of Wnt/β-catenin signaling resulted in the 
differentiation of hESCs into primitive streak and mesoderm progenitors [33, 34]. Inhibition 
of Wnt/β-catenin signaling by blocking the secretion of Wnt [31] or by stabilizing β-catenin 
destruction complex [28] augments the self-renewal and long term propagation of human 
ESCs. It was additionally shown that Wnt-signaling promotes cell proliferation of hESC with 
little effect on apoptosis. This agrees well with the known gene targets upregulated by Wnt-
signaling pathway such as cyclin D1 [32, 33], and c-Myc [34]. In short, while Wnt-pathway’s 
pro-proliferative effect may be important in self-renewal of hESC, its importance in the 
maintenance of pluripotent state is unclear. 
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1.1.2 The role of oxygen tension in embryonic stem cells. 
The natural niche of early embryonic cells is enriched with essential growth factors 
and the proper microenvironment for the maintenance of self-renewal and pluripotency, and 
this often includes low oxygen tensions [36, 37]. Early embryonic cells grow under low 
oxygen availability starting from fertilization and continuing through implantation and fetal 
development. During implantation, a hypoxic environment is created due to the absence of 
oxygen provided from maternal circulation [37]. The uterine surface typically has oxygen 
concentrations of 2% in early pregnancy. The oxygen tension rises to approximately 8% once 
the maternal vasculature is established [38]. Oxygen acts as the final electron carrier in the 
ETC of OXPHOS-dependent energy metabolism in mammalian cells [39]. During early 
embryo development, cells adapt to the low oxygen environment by switching between 
OXPHOS-dependent and glycolysis-dependent energy production [40].  
hESCs derived from the early embryo grow relatively well under ambient oxygen 
tension (~21%) without apparent negative consequences. However, closer examination 
revealed the effect of oxygen tension on altered hESC morphology [42-44], pluripotency and 
differentiation marker expression [44, 45], cloning efficiency [43], chromosomal stability[44] 
and differentiation capacity [42, 43]. In the majority of the studies, low oxygen tension (2–
5%) improved human ES cell pluripotency and maintenance [44– 47]. In addition, low 
oxygen condition (5%) was shown to improve the efficiency of iPS generation from human 
dermal fibroblast cells [48], further supporting the notion that stemness of hESC is 
augmented by hypoxia. Notably, conflicting results do exist to suggest that oxygen tension 
has minimal to no effect on the stemness of hESCs [43, 48].  
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In murine ESCs, hypoxia-inducible-factor1 alpha (HIF1A) plays a central role in 
regulating the cellular response to oxygen availability, mediating the expression of many 
oxygen-related genes [50]. While HIF1A controls a broader spectrum of oxygen-dependent 
genes, HIF2A is a direct upstream regulator of POU5F1 (OCT4) in mouse ES cells [51]. In 
hESCs, HIF1A is only transiently expressed for approximately 48 hours following hypoxic 
exposure [52], suggesting a long-term hypoxic regulation by a factor other than HIF1A. 
Indeed, HIF2A was described to be responsible for the regulation of energy metabolism and 
self-renewal in hESCs grown under 5% oxygen tensions [53].  
1.1.3 Energy Metabolism of Pluripotent Stem Cells 
 Prior to vasculature formation, early-stage embryonic cells grow in a hypoxic 
environment (1-5%) [38, 53]. PSCs such as hESCs and mouse epiblast-derived stem cells 
(mEpiSC) exhibit low-level cellular respiration and down-regulation of electron transport 
chain (ETC) activity, while enzymes involved in glycolytic pathways are up-regulated [11]. 
This reliance on glycolytic metabolism is partly explained by the hypoxic micro-
environmental condition of pre-implantation embryos [55]. Consequently, ATP synthesis in 
PSCs is primarily produced via glycolysis and pyruvate is converted into lactate instead of 
being fed into the Krebs cycle [13, 55]. hESCs’ reliance on glycolysis is achieved by up-
regulation of Glut1/3 [57], hexokinase2 (HK2) [55], phosphofructokinase (PFK) [58], and 
inactivation of mitochondrial ETC enzymes such as pyruvate dehydrogenase (PDH) [55]. 
Moreover, hESCs up-regulate UCP2 uncoupler protein, which in turn suppresses oxidative 
phosphorylation (OXPHOS) by actively shunting out C4 metabolites from mitochondria 
matrices [59]. In agreement with the suppressed mitochondrial glucose oxidation, 
mitochondria of hESC are structurally and functionally immature with underdeveloped 
cristae [55]. Conversely, differentiation of hESC is accompanied by rapid maturation of 
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mitochondria and increased metabolism via OXPHOS [60]. Glycolytic energy metabolism of 
hESCs serves to protect the cells from DNA damage by minimizing reactive oxygen species 
(ROS) generated through OXPHOS [55]. Although oxygen consumption is decoupled from 
ATP generation in ESCs, some level of oxygen consumption appears to be important, 
possibly to maintain functional tricarboxylic acid (TCA) cycle for lipid and protein synthesis 
by NADH oxidation to NAD+. Interestingly, PSCs do not experience a metabolic shift from 
glycolysis to OXPHOS in presence of sufficient oxygen, which closely resembles Warburg 
metabolism in cancer cells [55]. In the context of cancer cells, the aerobic glycolysis provides 
an anabolic advantage to support rapid cell growth. It is speculated that glycolysis endows a 
similar advantage in PSCs, whose key defining characteristic is high proliferative capacity. 
For instance, mouse ESCs show increased activity in pentose phosphate pathway and use it to 
generate carbon intermediates, which allows rapid nucleic acid synthesis [61]. Moreover, 3-
phosphoglycerate can be converted into 3-phosphoserine and eventually into serine/glycine 
to be used for nucleotide biosynthesis and mono-carbon metabolism. One of the defining 
hallmarks of the Warburg phenomenon is rapid glutamine consumption that is used as an 
alternative carbon source for TCA cycle. Glutamine is the most abundant free amino acid in 
human plasma [62]. Glutamine is first converted into glutamate and subsequently to a key 
carbon component of TCA cycle alpha-ketoglutarate. The carbon intermediates generated 
through TCA minimally contribute to OXPHOS-dependent ATP synthesis. Instead, they are 
used for anabolic processes such as lipid (from citric acid pathway) and amino acid synthesis 
(alpha-ketoglutarate, oxaloacetate). In addition to methionine, threonine is another amino 
acid critical for mESC metabolism and proliferation. Threonine contributes to the pool of 
acetyl-CoA and glycine through L-threonine dehydrogenase (TDH) in mitochondria. Glycine 
then contributes directly to nucleotide biosynthesis or indirectly to S-adenosyl-methionine 
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(SAM) production by modulating tetrahydrofolate’s (THF) conversion to L-methyl-
tetrahydrofolate (mTHF). Threonine deprivation in mESCs leads to the reduction in the 
trimethylation of histone 3 lysine 4, increasing the propensity to differentiate [63].  
The importance of mitochondria is also seen in reprogramming of somatic cells to 
induced pluripotent stem cells (iPSCs). During conversion of somatic cells to a pluripotent 
state, depleting mitofusin proteins (MFN1/2) promotes the reprogramming efficiency by 
increased mitochondria fission [64]. Similarly, the reprogramming efficiency of somatic cells 
into iPSCs is enhanced three- to four-fold when glycolysis is promoted, and is reduced when 
glycolysis is inhibited [48]. Several pieces of evidence suggest that mitochondrial maturation 
and subsequent rise in intra-cellular level of reactive oxygen species (ROS) are required 
signaling elements in regulating both stem cell function and differentiation potential [54, 63– 
65]. Conversely, use of potent antioxidant vitamin C improves somatic cell reprograming 
efficiency by reducing intra-cellular ROS and by modifying the epigenetic landscape [68]. 
The significance of mitochondrial function and nuclear-mitochondrial cross-talk in stem cell 
biology remains yet poorly understood. The functional significance of mitochondria-
dependent metabolites in the self-renewal, pluripotency, and induction of PSCs calls for a 
closer investigation. 
1.1.4 Telomerase and Telomere in Human Embryonic Stem Cells 
Telomeres are linear DNA structures at the end of chromosomes. They are non-coding 
DNA buffer regions that shorten with each DNA replication event due to the “end-replication 
problem” of eukaryotic DNA polymerase. For actively proliferating cells such as hESCs, 
maintaining the telomere homeostasis is critical for the function and longevity of the cells. A 
few mechanisms exist to maintain telomere lengths. In mice, both the telomerase and 
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alternative lengthening of telomere (ALT) pathway are utilized to maintain telomere lengths. 
In human cells, ALT is utilized to a lesser extent and telomerase activity is the primary 
means for maintaining telomere homeostasis. A ribonucleoprotein called telomerase is highly 
upregulated in hESCs for this reason, and the stable telomerase activity and long telomere 
lengths are characteristic of hESCs. Telomere lengthening via telomerase is activated as early 
as the blastocyst stage of embryo development in mice and high telomerase expression 
becomes absent in most adult somatic cells with exception of the germ line [69] and activated 
lymphocytes [65-69]. Of note, several stem cell types, their proliferative capacity 
notwithstanding, exhibit low to moderate telomerase activity and experience telomeric 
shortening. To date, most telomerase/telomere studies have been conducted with mouse 
embryonic stem cells (mESCs). In mESCs, the loss of telomerase activity results in telomere 
shortening, genomic instability, and reduced growth rates. Moreover, PSCs with long 
telomere lengths exhibit higher chimera success rate in tetraploid complementation assays 
than those with short telomeres [72]. These results suggests that telomere maintenance by 
telomerase is crucial for the proper functioning of pluripotent stem cells.   
 
1.2  Human Telomerase Catalytic Subunit hTERT 
1.2.1 Canonical Function of hTERT 
 The telomerase ribonucleoprotein (RNP) complex was first discovered in 
Tetrahymena by Elizabeth Blackburn and Carol W. Greider [73]. The human homologue of 
telomerase RNP was soon characterized [74], and was found to consist of catalytic protein 
subunit hTERT (127kDa) and RNA component called hTERC [75]. The active form of the 
telomerase complex requires dimerization of these components, and lack of either of these 
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components or the failure to dimerize result in loss of telomerase activity [76]. hTERC is a 
non-coding RNA that acts as a template for telomere sequence elongation. Using hTERC, 
hTERT adds multiple hexameric DNA repeats (TTAGGG) to the telomere ends. This 
canonical function of telomerase is strictly regulated at multiple levels. Transcriptionally, the 
pre-messenger RNA of hTERT gets spliced to generate various alternative transcripts (23 
different alternatively spliced transcripts to date) with disrupted catalytic domain, ultimately 
resulting in a decreased pool of mRNA for catalytically active hTERT [75, 76]. Several 
studies have observed that the splicing pattern changes in a cell type-, and developmental 
stage-dependent manner, suggesting that alternative splicing is likely a tightly controlled 
regulatory mechanism for telomerase activity [77– 80]. However, the means or the effect of 
alternative splicing of hTERT on telomerase activity remains largely unknown (see section 
1.2.2). Telomerase activity is also regulated post-translationally through phosphorylation and 
ubiquitination (see section 1.2.4). hTERT has a relatively short half-life of approximately 24 
hours due to its fast-turnover rate through ubiquitination [83]. Interestingly, the RNA 
component hTERC is rarely the limiting factor for telomerase activity [73, 82]. Unlike 
hTERT, hTERC is ubiquitously expressed in most cell types, which appears to be 
independent of TERT levels [75]. However, in a pathological setting such as in the premature 
aging syndrome dyskeratosis congenita where TERC could be mutated or lacking, telomerase 
activity is inhibited [83, 84].  
 
1.2.2 Alternative splicing of hTERT 
Ninety five percent of protein coding genes are affected by alternative splicing in 
multicellular eukaryotes, generating >100,000 proteins from 20,000 protein-coding 
10 
 
 
 
sequences [87]. The canonical mode of RNA splicing entails joining of exonic sequences via 
the removal of the noncoding intron sequences. Splicing events occur on the nascent pre-
mRNA, simultaneously with transcription [86, 87]. The event is orchestrated by a large and 
dynamic ribonucleoprotein called the spliceosome. A spliceosome is composed of snRNP 
core components (U1, U2, U4, U5, and U6) and other accessory proteins (~300 proteins) 
[90]. An exon may be constitutively included in the final transcript (constitutive splicing) or 
be conditionally included (alternative splicing), leading to alternative transcripts. Various 
local cis-regulatory sequences such as exonic splicing enhancers (ESEs), exonic splicing 
silencers (ESSs), intronic splicing enhancers (ISEs), and intronic splicing silencers (ISSs) 
regulate alternative splicing with the help of trans-acting elements such as snRNPs 
(activators), hnRNPs (repressors), and polypyrimidine tract binding protein (PTB)[89-91]. A 
clear understanding of splicing mechanisms is hampered by the vast number of splicing 
factors (>500), and by involvement of other cellular processes that affect spliceosome 
assembly. The selection of cis-elements is influenced by the molecular kinetics of 
transcription, 5′-end capping, and 3′-end polyadenylation [92, 93]. The complexity of 
alternative splicing is compounded by the competition of various transcripts for the splicing 
machinery [95].  
The human TERT (hTERT) gene contains 15 introns and 16 exons and its transcript 
is alternatively spliced to produce various insertion and deletion isoforms [96]. Multiple 
alternative splicing events can occur on a single transcript, greatly expanding the pool of 
possible hTERT transcript variants. To date, 22 hTERT transcript variants have been 
identified [97]. However, translational competency of the identified alternatively spliced 
transcripts remains largely unknown. Amongst these, only the full-length hTERT (hereafter 
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referred to as FL-hTERT) constitutively spliced transcript (transcript with sixteen 
uninterrupted exons) results in a TERT protein capable of reverse transcriptase activity [97, 
98].  
An hTERT isoform called the β-deletion hTERT (hereafter referred to as β-hTERT) 
results from a 182-nucleotide out-of-frame deletion and is amongst the best characterized. 
The deletion skips exons 7 and 8, and joins exon 6 to exon 9 (see Fig. 1.1).The frame shift 
introduces a premature termination codon (PTC) and results in truncation of the hTERT 
protein [99, 100]. Splicing of β-hTERT is enhanced by serine/arginine-rich splicing factor 11 
(SRSF11), and repressed by hnRNPH2 and hnRNPL [102]. Another study conducted by 
Wong et al. identified three highly conserved (amongst primates) direct repeat sequences in 
introns 6 and 8 [103]. The repeats in intron 6 (called block 6 and direct repeat 6 by the 
author) promoted β-deletion while the repeat in intron 8 (called direct repeat 8) repressed it. 
Importantly, block 6 is necessary for β-deletion splicing. Despite the PTC, it was reported 
that β-deletion transcripts escape non-sense mediated decay (NMD) and are translated into 
proteins [102]. There is currently no report on β-hTERT’s propensity to degrade through 
protein degradation pathway. The β-hTERT contains an incomplete reverse-transcriptase 
domain and therefore was not considered a direct contributor to telomeric lengthening. 
However, Listerman et al. reported that β-hTERT acts as dominant-negative regulator of 
telomerase activity by sequestering hTERC [102]. Interestingly, β-hTERT transcript persists 
during human fetal development even when FL-hTERT splicing diminishes in various tissues 
in a development-stage-specific manner during fetal gestation [104]. Accumulating evidence 
indicates that either an increase or decrease in FL-hTERT transcript levels (and subsequent 
telomerase activity) may come at the expense of β-hTERT transcript abundance, further 
increasing the likelihood of regulatory functions by β-hTERT [100, 104-106].  
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The α-deletion hTERT (hereby noted as α-hTERT) results from a partial in-frame 
deletion (36bp) of exon 6, leading to the partial loss of RT-motif A. This catalytically 
inactive form of hTERT is a dominant negative inhibitor of telomerase activity when 
overexpressed in telomerase positive immortal cells [98, 107]. Considering the relatively low 
transcript abundance of the α-hTERT [108, 110], the level of telomerase activity inhibition 
by α-hTERT may be insufficient for it to have significant impact on telomere maintenance of 
indefinitely dividing cells. Following the discovery of the α-hTERT, Hisatomi et al. 
discovered another catalytically inactive variant (γ-hTERT) with two missing RT-motifs 
[110]. Like the α-hTERT, the γ-hTERT was suggested as a negative regulator of telomerase 
activity. However, γ-hTERT transcript levels, relative to those of α-hTERT and β-hTERT, 
are extremely low or nearly undetectable in all tested cell types [111-112]. Deletions at α and 
β sites can occur simultaneously on a single transcript generating truncated and catalytically 
inactive α-β-hTERT [112]. The function, splicing mechanisms, and protein stability of this 
isoform yet remain to be elucidated.  
Telomerase activity requires dimerization of two catalytically active forms of hTERT 
[76]. Therefore, all translated hTERT splice variants that contain an oligomerization domain 
can potentially suppress telomerase and/or extra-telomeric functions of FL-hTERT by 
forming heterodimeric complex with it (Figure 1.1) 
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Figure 1.1: mRNA and protein structure of the major hTERT isoforms. A) Transcript 
structures of FL-hTERT, α-hTERT, and β-hTERT post-splicing. The deletion site and the 
open reading frame (ORF) of each isoform are indicated. B) Protein structure of hTERT. 
Regulatory domains/residues on the protein are annotated. 
14 
 
 
 
1.2.3 Transcriptional Regulation of hTERT 
An intricate regulation of hTERT expression is orchestrated by several transcription 
factors and DNA/histone modifying complexes at the promoter region. HSP90 (whose 
involvement is important for telomerase DNA binding and association with hTERC [113], 
[123, 124] was found to interact with the hTERT promoter in immortalized and cancer cells, 
regulating hTERT transcription [116]. Inhibition of HSP90 causes hTERT transcription and 
telomerase activity to decrease, which occurs concurrently with the diminished interaction of 
HSP90 with the hTERT promoter [116]. It is postulated that HSP90 may associate with GC-
box-binding transcription factors such as Sp1 [116]. GC-boxes are important regulatory 
regions of the hTERT promoter that lacks a TATA-box [126, 127]. The hTERT promoter 
contains a minimum of five GC-boxes, and mutations in these regions severely impair the 
transcriptional activity at the site [116]. Notably, Sp1’s interaction with the hTERT promoter 
is not disrupted by inhibition of HSP90, but there has been a report on their cooperative 
coordination of other GC-box-containing gene expression [119], suggesting an auxiliary 
function of HSP90 in Sp1-driven hTERT transcription. The significance of Sp1 in hTERT 
regulation is a controversial one. As demonstrated by Cheng et al., both Sp1 and its related 
transcription factor Sp3 are required at the hTERT promoter for its transcription [120]. This 
agrees with previous reports that Sp1-family proteins generally activate hTERT transcription. 
Conversely, the repressive role of Sp1/3 has also been reported in normal human somatic 
cells [121]. Notably, the epigenetic state of the hTERT promoter appears to have little effect 
on Sp1 binding. Conversely, binding of Sp1/3 does not affect H3K9 (histone 3 lysine 9) 
acetylation or trimethylation status. It is postulated that hTERT transcriptional 
activation/repression by Sp1/3 may be dependent on other cell-type/-state specific factors, 
and that the recruitment of the complex to the promoter is relatively insensitive to the 
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epigenetic state of the target site [121]. Nonetheless, the heterochromatin-like state of the 
hTERT gene must become more open landscape for transcription factors’ access to the GC-
boxes and the eventual promoter activity in telomerase positive cells [120].  
E-box transcription factors, Myc family proteins, and USF1/2 are believed to be the 
key de-repressors of the hTERT promoter via the recruitment of histone-modifying 
complexes [120]. The E-box transcription factors were found to be clustered around the 
hTERT promoter, possibly to promote an open conformation of the site. However, such 
occupation by E-box transcription factors at the hTERT promoter is seen even in telomerase-
negative cells. This implies an involvement of additional factors to initiate the remodeling of 
heterochromatins [120]. In the same study, it was demonstrated that the rate of hTERT 
transcription was directly proportional to the establishment of a nucleosome-free region (also 
known as a DNAse I hypersensitive site (DHS; euchromatic) in the hTERT promoter of 
telomerase positive cells [120]. Chromatin remodeling events are not unique for GC-boxes as 
they can also take place at estrogen response elements (EREs) in the hTERT promoter of 
estrogen-receptor-α-positive cells [122]. In addition, retinoic acid hormone receptor family 
proteins can repress hTERT transcription by reducing H3K9 acetylation (change to 
heterochromatic state) and by promoting methylation at the promoter region (repressive 
marker) [132, 133]. Such hormonal control of hTERT transcription has significant impact on 
the up-regulation of hTERT by oncogenic transcription factors such as c-Myc and HIF1A. 
[134, 135], both of which are direct positive-regulators of hTERT transcription [136, 137]. 
While the transcriptional control by various transcription factors and chromatin remodeling 
proteins is an important step in hTERT regulation, mounting evidence indicates that post-
translational modification mechanisms play critical roles in determining the end-function of 
the hTERT protein (discussed in the following section). 
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1.2.4 Post-translational activation/repression of hTERT 
hTERT is primarily regulated at the transcriptional level [113, 114], but regulation by 
post-translational mechanisms, such as phosphorylation and ubiquitination, has been reported  
and thought to be important [113, 115]. New discoveries regarding the post-translational 
regulation of hTERT are continuously emerging.  
Two known mechanisms of post-translational regulation of hTERT are by 
phosphorylation and ubiquitination (Figure 1.2). The best characterized degradation process 
of hTERT occurs through ubiquitination by Makorin Ring Finger Protein 1 (MKRN1, 
interacts with hTERT C-terminal residues 946–1132)[129], C terminus of HSC70-Interacting 
Protein (CHIP)[130], and HDM2 (E3 ligases)[131]. Ubiquitinated hTERT is subsequently 
targeted for destruction by proteasomes in the cytoplasm. The exact mechanisms of 
ubiquitination remain to be elucidated. The fact that the ubiquitination and degradation 
processes of hTERT take place in the cytoplasmic space makes hTERT’s sub-cellular 
localization a critical factor in hTERT regulation. In line with this, one dominant negative 
form of hTERT was proposed to promote the degradation of FL-hTERT by exporting itself 
out of nuclei with the FL-hTERT (as heterodimeric complex), where hTERT becomes 
available for ubiquitination and for the subsequent proteolysis [132] in MCF-7 cells, 
ultimately reducing telomerase activity [133]. Sphingosine-1-phosphate (S1P) is another 
bioactive lipid mediator of hTERT degradation [134]. Allosteric binding of S1P to hTERT 
mimics a phosphorylated residue at aspartate 684, which in turn prevents the interaction of 
MKRN1 with hTERT (therefore stabilizes hTERT against proteolysis). It was also shown by 
the same group that a similar phosphomimetic substitution by S1P occurs at serine 921, 
protecting hTERT from degradation while keeping them in the nuclear region. 
17 
 
 
 
Activation of hTERT is primarily regulated by a series of phosphorylation events 
caused by various kinases and adaptor proteins. Phosphorylation of hTERT by protein kinase 
C (PKC) isoenzymes alpha, beta, delta, epsilon, and zeta phosphorylate hTERT, thereby 
enhancing telomerase activity [144, 145]. The mechanism of this remains unclear. hTERT 
contains a consensus bipartite nuclear localization signal (NLS) consisting of two clusters of 
basic amino acids (222RRR224 and 236KRPRR240)[137]. Additionally, putative Akt-
phosphorylation sites are located at 220GARRRGGSAS229 and 817AVRIRGKSYV826, and the 
phosphorylation of serine 227 (but not serine 824) is required for nuclear translocation of 
hTERT [138]. Chung et al. [137] predicted that the observed post-translational modification 
by Akt may result in a conformational change of hTERT, generating new interaction sites for 
binding partners like p65 of nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) family proteins [139]. Similarly, Polo-like kinase 1 (Plk1) is believed to augment 
telomerase activity by promoting the nuclear retention of hTERT (thereby preventing the 
proteosomal degradation of hTERT in the cytoplasm) [140]. In support of this, 
overexpression of Plk1 resulted in increased hTERT protein levels without changing the 
steady-state transcript level of hTERT [140]. However, Plk1 does not phosphorylate hTERT, 
nor does it affect its interaction with hTERT [140]. Conversely, extra-nuclear localization of 
hTERT is regulated by the phosphorylation of Src tyrosine kinase at tyrosine 707 [141]. Src-
mediated tyrosine 707 phosphorylation enables binding of Ran GTPase to hTERT, and the 
subsequent nuclear export via the chromosomal maintenance 1 (CRM1) export receptor 
[142]. 14-3-3 protein can bind hTERT and prevent its cytoplasmic localization by inhibiting 
CRM1-hTERT interaction [143]. Contrarily, dephosphorylation of hTERT by the 
phosphatase PP2A blocks the interaction between 14-3-3 and hTERT, thereby disrupting the 
nuclear localization and telomerase activity [144].  In the context of mitochondrial 
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localization, Src (mitochondrial)-mediated phosphorylation at Y707 was also shown to be 
responsible for the depletion of mitochondrial hTERT following H2O2-treatment [141]. In the 
same study, H2O2 treatment led to the reduced activity of mitochondria-resident Akt, 
suggesting Akt may regulate hTERT function not only in the nuclei, but also in the 
mitochondria [141]. Another tyrosine kinase Abelson murine leukemia viral oncogene 
homolog 1 (c-Abl) is a negative regulator of telomerase activity. c-Abl directly interacts with 
hTERT (at 308PSTSRPPRP316) and induces tyrosine phosphorylation of hTERT in MCF-7 
cells following ionizing radiation, reducing telomerase activity. However, the exact location 
of phosphorylated amino acid residue and the mechanism remain to be investigated [133]. 
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Figure 1.2: Post-translational modification and function of hTERT. Summary of 
signaling molecules/pathways that regulate the intra-cellular movement/stability of hTERT. 
hTERT is recruited to nuclear space for telomerase activity (section 1.2.1) and extra-
telomeric functions (section 1.3.1-1.3.3). Conversely, hTERT is exported out of nucleus for 
ubiquitin-mediated degradation (section 1.2.4) or is targeted to mitochondria for 
mitochondrial functions (section 1.3.4). Factors/signaling-pathways that regulate hTERT 
translocation are indicated beside the arrows.   
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1.3      Non-canonical functions of Human Telomerase Catalytic Subunit hTERT 
1.3.1 Non-Canonical Functions of hTERT in Wnt/β-catenin pathway 
hTERT participates directly with Wnt/β-catenin to regulate downstream gene 
expression [145]. Wnt-signaling governs cell proliferation, and its involvement is critical for 
proper axis formation during embryo development. Three known modes of Wnt-signaling 
pathways are Wnt/calcium pathway, planar cell polarity pathway, and the canonical Wnt/β-
catenin pathway [145]. The canonical signaling cascades starts when extra-cellular signaling 
Wnt family proteins bind to the N-terminal extra-cellular cysteine-rich domain of Fizzled 
(Fz) family receptor and lipoprotein receptor-related protein (LRP)-5/6 [145]. The binding of 
Wnt to Fz and LRP-5/6 leads to the dephosphorylation of a negative regulator of Wnt-
signaling called Axin. This subsequently causes the disruption of protein degradation 
machinery (consisting of adenomatosis polyposis coli (APC), protein phosphatase 2A 
(PP2A), glycogen synthase kinase 3 β (GSK3β), which otherwise marks β-catenin for 
degradation by ubiquitination. The stabilized β-catenin eventually accumulates in nuclei to 
initiate the cellular response with the help of other transcription factors such as T-cell 
factor/lymphoid enhancing factor (TCF/LEF) and BRG1 [146]. It was demonstrated by Park 
et al. [147] that murine TERT (mTERT) modulates Wnt/β-catenin by acting as a cofactor of 
transcription complexes that consists of TCF/LEF and BRG1 (SMARCA4). Another group 
also confirmed TERT’s association with BRG1 (Brahma-related gene 1) in human cells 
[148].  However, a contradicting result presented by Elizabeth Blackburn’s group [149] 
showed that hTERT did not associate with BRG1. The discrepancy may arise from cell type-, 
and species specific differences. Interestingly, β-catenin was found to be a positive and direct 
regulator of hTERT gene expression through the interaction with Klf4 (in mouse ES cells) 
[150], and TCF4 (in human cancer cell) [151] at the transcription start site, suggesting a feed-
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forward regulation between Wnt-signaling and hTERT expression. BRG1, on the other hand, 
suppresses hTERT expression by forming a ternary complex with HDAC2, leading to 
deacetylation of H3K9ac and H4ac at the transcription start site of hTERT in human cancer 
cells [152].  
1.3.2 Non-Canonical Functions of hTERT in NF-kB pathway 
Several groups have shown that TERT regulates NF-κB-dependent gene transcription 
in the absence of any telomere-mediated effects [156, 166-168]. The NF-κB signaling 
pathway is a master regulator of cell stress, inflammatory response, and developmental 
signaling [169- 171]. NF-κB protein family proteins include p50, p52, RelA (p65), RelB, c-
Rel. The canonical NF-κB signaling involves dimerization of p65/p50 subunits (stabilized 
through the degradation of I-kappa-B-alpha (IκBα)) to regulate the expression of target 
genes. NF-κB is strongly activated in cancer cells, which led more researchers to investigate 
the potential regulatory cross-talk between hTERT and NF-κB. The studies have revealed 
that NF-κB positively regulates TERT by directly binding to its promoter [157]. In 
agreement, it was demonstrated that hTERT’s nuclear translocation and telomerase 
activity/expression were enhanced by the binding of p65 in MM.1S cells [173, 174]. 
Additionally, Ghosh et al. recently discovered that hTERT directly regulates the expression 
of the NF-κB-dependent genes by binding to p65, and localizing to a subset of NF-κB sites, 
on promoters of IL-6, TNF-α and IL-8 [166, 167]. In the same study, results indicated that 
TERT is not merely a co-factor, but a requirement for optimal p65 binding to a few NF-κB 
target genes when NF-κB signaling was induced by TNF-α stimulation [153]. Ghosh et al. 
clarified this further by identifying telomere like sequences (TTGGG) within the promoter 
regions of IL6A, IL8A and TNF-α genes [153].  
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Not much is known about NF-κB signaling with respect to the pluripotency and self-
renewal of PSC. However, the gene expression/proteome profiling of undifferentiated and 
differentiated ESCs show that components of the NF-κB signaling pathway are enriched in 
undifferentiated hESC, and downregulated during differentiation. Immunohistochemistry of 
RelA showed that it is only present in the nucleus of undifferentiated hESC, indicating active 
NF-κB signaling. To test the potential importance of NF-κB signaling in the maintenance of 
pluripotency, a specific NF-κB inhibitor sodium pyrrolidinethiocarbamate (PTDC) was 
added to the cells. PTDC prevents RelA (p65) entry into the nucleus. Inhibition of NF-κB 
signaling by PTDC caused massive cell differentiation within ESC colonies, as well as 
significant cell death, demonstrating that NF-κB, or at least the nuclear translocation of 
hTERT mediated by NF-κB molecule p65, is essential to maintain ESC pluripotency [18]. 
The downregulation of NF-κB signaling was also observed in spontaneously differentiating 
human ESCs.  In another study with three independent human iPSC lines, the augmented 
level of NF-κB signaling was confirmed. Moreover, the knockdown of NF-κB resulted in 
decreased Nanog and Oct-3/4 expression levels, suggesting an important role of NF-κB in the 
maintenance of undifferentiated human PSCs [161]. In contrast, NF-κB signaling is 
suppressed in undifferentiated mouse ESCs and activated in differentiating mouse ESCs 
[176, 177].  Torres et al. reported that a pluripotency transcription factor Nanog represses 
NF-κB signaling to promote pluripotency. Taken together, the studies point to the importance 
of NF-κB signaling and its cross-talk with hTERT in modulation of pluripotency in human 
PSCs.  
1.3.3 Non-Canonical function of hTERT as an RNA-dependant RNA Polymerase (RdRP) 
Several pieces of scientific evidence exist to show that TERT plays a direct role in the 
regulation of gene expression, including Wnt/β-catenin and NF-κB pathways just reviewed. 
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In more recent years, several reports show that TERT may regulate gene expression at the 
post-transcriptional level in an extra-telomeric fashion [157, 178, 179]. Maida et al. showed 
that hTERT can interact with non-TERC RNA species called RNA component of the 
mitochondrial RNA-processing endoribonuclease (RMRP) to form a ribonucleoprotein 
complex that has RNA-dependent RNA polymerase activity. The resulting reverse 
transcriptase TERT-RMRP complex generates double stranded RNA (dsRNA) using RMRP 
as a template RNA strand. The dsRNAs are subsequently processed by Dicer1 into 22-
nucleotide small-interfering RNAs (siRNAs) that selectively cleave and silence themselves. 
RMRP is a 267 nucleotide-long non-coding RNA that is highly expressed in many human 
and murine tissues. Notably, RMRP expression is activated by Wnt/β-catenin and YAP 
proteins in human carcinoma cells [166], suggesting TERT-RMRP complex may be a part of 
much broader signaling pathway. The canonical role of RMRP is implicated in mitochondrial 
DNA replication where it initiates the replication process by cleaving another mitochondrial 
RNA (inhibits progression of mitochondrial DNA replication) bound at the priming site 
[167]. Mutations in the RMRP gene are associated with cartilage hair hypoplasia (CHH) 
[182, 183]. Homozygous deletion of RMRP in mouse results in embryonic lethality, 
indicating RMRP is essential for early mouse embryonic development [165].  Sharma et al. 
(a team led by a pioneering scientist to show mitochondrial effects of hTERT) suggested the 
mitochondrial hTERT binds different mitochondrial RNAs and carries out its tentative 
mitochondrial functions (see section 1.2.4) in TERC-independent manner [170]. The study 
raised possibilities that there may be more RNA binding partners other than RMRP to 
regulate gene expression in the mitochondria. 
Outside of mitochondrial context, hTERT was shown to regulate heterochromatin 
assembly at centromeres and transposon elements on chromosomes [148]. hTERT associates 
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with BRG1 and nucleostemin (NS) to form a TBN (TERT, BRG1, and Nucleostemin) 
complex with RdRP activity. The complex produces dsRNAs homologous to centromeric 
alpha-satellite (alphoid) repeat elements. The dsRNA is then processed into siRNAs that 
target the centromeric alphoid regions to promote the recruitment of heterochromatin 
assembly complexes to the site. In a different study by the same group, it was shown that 
siRNA generated via RMRP-hTERT RdRP and RNA-induced silencing complex (RISC) 
negatively regulated PHYHIPL transcript level whose cellular functions are yet unclear 
[171].  Even though there has been no report to indicate the functional significance of hTERT 
as TERC-independent RdRP in hESCs, the mounting evidence of it in other cell types 
suggest hTERT may carry out important nuclear and mitochondrial roles in hESCs 
independently of TERC. 
1.3.4 Mitochondrial Functions of hTERT 
 Santos et al. (2003) [172] have shown that ectopically expressed TERT exacerbates 
H2O2-mediated mitochondrial damage in human cells. They delineated this phenomenon by 
identifying the putative 20 amino acid-long mitochondrial localization signal at the very N-
terminal end of hTERT. hTERT associates with mitochondrial membrane translocases 
TOM20/40 and TIM23 proteins, further suggesting the mitochondrial localization of hTERT 
[173]. Mitochondrial DNA has 22 sites with telomere-like sequences for hTERT binding, and 
hTERT’s binding to two of these sites has been confirmed [173]. The bound regions of 
mitochondrial DNA each code for complex 1 NADH-Ubiquinone Oxidoreductase chain 1 
and 2 subunits [173]. Ectopic expression hTERT up-regulates complex I activity [173]. 
Conversely, ectopic expression of catalytically inactive hTERT results in decreased complex 
I activity. Other known mitochondrial effects of overexpressed FL-hTERT include increased 
mitochondrial membrane potential, down-regulated UCP2 (uncoupler of mitochondria that is 
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responsible for repressing OXPHOS in PSCs), reduced mitochondrial superoxide, 
mitochondrial DNA (mtDNA) content, and mitochondria mass [174]. 
 It was suggested that ectopically expressed hTERT lead to increased H2O2-mediated 
mtDNA damage through increased availability of metal ions [175]. However, other studies 
demonstrate that FL-hTERT protects mtDNA from H2O2-induced oxidative stress[142], 
[174]. In addition, FL-hTERT protects mtDNA from other genotoxins such as ethidium 
bromide and UV-light. In general, hTERT appears to augment mitochondrial function and 
maturation. A growing body of research suggests that TERT has important effects on 
mitochondrial function in a telomere-independent manner [187, 190-193]. However, the 
mechanism by which TERT protects mitochondrial function is not completely understood, 
and remains to be elucidated 
 
 
1.4 Rationale 
Mitochondria in undifferentiated hESCs are localized to the peri-nuclear space, and 
remain low in copy number and are punctuate in morphology [60]. In contrast, hESC 
differentiation is accompanied by the formation of a reticular network of maturing 
mitochondria with a simultaneous increase in OXPHOS and ROS production [66]. Taken 
together, mitochondrial function and biogenesis is key to understanding the regulation of 
pluripotency in undifferentiated hESCs and in early differentiation processes [178]. 
hTERT can interact with a wide range of biomolecules such as DNA [187, 195], 
transcription factors [156, 166], a helicase [180], and various species of RNA [157, 185, 196-
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198]. Thus, hTERT has various functions in the nucleus and mitochondria. Interestingly, a 
number of these hTERT functions require catalytically activity of hTERT [181] and is often 
inhibited by catalytically inactive forms [98, 108, 187]. Many past studies [175–177, 187, 
188] and our lab’s previous work by Radan et al. [184] demonstrated that high oxygen 
tension and oxidative stress on cells induce the extra-nuclear/mitochondrial localization of 
hTERT. Radan et al. additionally showed that pharmacological inhibition of telomerase 
activity, but not TERC, resulted in spontaneous differentiation of hESC. Similarly, disrupting 
β-splicing by morpholino oligonucleotides in hESC resulted in loss of pluripotency, 
indicating the importance of hTERT and its non-catalytic variants in stem cell function [184]. 
Yang et al. [185] had also shown the importance of hTERT in hESC maintenance through 
knockdown studies. β-hTERT, like its full-length counterpart, has an intact MTS [172], 
RNA-interacting domains [199, 200], and oligomerization sequence[188], and retains some 
phosphorylation sites for nuclear import [201, 152] and export [142] (Figure 1.1). Listerman 
and colleagues recently demonstrated that β-hTERT is capable of mitochondrial localization 
in HeLa cells [102]. However, the cause and the pattern of β-hTERT localization is currently 
unknown. This mitochondrial localization may allow β-hTERT to alter the function of FL-
hTERT in any subcellular compartment by sequestering key functional components such as 
specific RNA components or by disrupting the formation of a functional homodimer of 
catalytically active hTERT subunits. 
Following the relatively recent discovery of hTERT localization to mitochondria, 
several studies indicated that mitochondrial FL-hTERT may function through modulation of 
mitochondria biogenesis, retrograde response to oxidative stress, and changes in divalent 
metal ion homeostasis  [186-188].  It was demonstrated that FL-hTERT interacts with 
mtDNA, and enhances mitochondrial function [173]. Notably, overexpression of a reverse-
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transcriptase incompetent hTERT mutant abrogated this effect [173]. Considering β-hTERT 
is a reverse-transcriptase incompetent form, there may exist an interaction between FL-
hTERT and β-hTERT in mitochondria to fine-tune mitochondria function, possibly through 
hetero-dimerization. Collectively, targeting of β-TERT to mitochondria and its potential to 
modulate mitochondrial function and growth may imply biological significance in the 
regulation of pluripotency, self-renewal and differentiation potential of PSCs. 
 
 
Hypothesis: Extra-telomeric hTERT β-isoform localizes to mitochondria under H2O2-
induced oxidative stress, modulating mitochondria function in hESCs. 
 
 
Objectives: 
1. To characterize FL-hTERT and β-hTERT expression and their role in modulating   
telomerase activity in hESCs. 
2. To characterize the mitochondrial localization pattern of FL-hTERT and β-hTERT in 
hESCs under H2O2-induced oxidative stress conditions.  
3. To determine the effect of overexpressed FL-hTERT and β-hTERT on mitochondrial 
biogenesis and function in hESCs. 
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Chapter 2: Material and Methods 
2.1 Cell Culture 
2.1.1 Mouse Embryonic Fibroblasts Feeder Cells 
Mouse embryonic fibroblasts (MEF) secrete several soluble growth factors to 
enhance the self-renewal and pluripotency of hESCs. For this reason, hESCs are often co-
cultured with irradiated MEF-feeder cells. Four drug (neomycin, hygromycin, puromycin, 
and 6-thioguanine)-resistant MEF(4DR-MEF) cells were purchased for the future use in 
drug-selection of cloned transgenic hESC populations. 4DR-MEF was cultured in DMEM 
medium (ThermoFisher) containing 10% fetal bovine serum, 1X Non-Essential Amino Acid 
(NEAA; ThermoFisher) under 5% CO2 at 37
oC. A bulk batch of MEFs was γ-irradiated to 
halt the cell proliferation and was cryo-preserved in small aliquots. γ-irradiated 4DR MEFs 
(approximately 60,000 cells and 106 for each well of 6-well plate and 10cm dish, 
respectively) were thawed and allowed to settle onto the culture dishes or plates for one day 
prior to being used as feeder-layer for hESC culture.  
 
2.1.2 Human Embryonic Stem Cell Line HES2 
The human ESC line HES2 was originally established in a fertility clinic in Singapore 
[190] and was purchased from ATCC for utilization in this study. For maintenance purposes, 
HES2 cells were cultured on γ-irradiated 4DR MEFs layer for a single passage (3-4 days to 
reach 70-80% confluency). hESC growth medium (83% KnockOutTM DMEM/F-12 
(GibcoTM), 15% KnockOutTM serum replacement (ThermoFisher), 1% GlutaMaxTM (X100; 
GibcoTM), 1% NEAA (X100; GibcoTM), 0.1% DMSO (Sigma), and 8ng/ml bFGF 
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(ThermoFisher)) was refreshed daily. The stably growing HES2 cells were subsequently 
expanded onto a feeder-free basement membrane GeltrexTM (Life technologies) in 2% O2 
(37oC, in 5% CO2) for experimental use. Fresh Essential 8
TM Medium (ThermoFisher) was 
supplied daily for feeder free hESC culture. Cells were treated with 100μM H2O2 for up to 4 
hours. 
 
2.1.3 Establishment of monoclonal transgenic HES2 lines. 
The lack of a reliable hTERT-specific antibody has been a challenge in studying FL-
hTERT, β-hTERT, and other TERT isoforms. To address this problem, my lab established 
clonally selected transgenic hESC cell lines capable of doxycycline-inducible overexpression 
of 3xFLAG-tagged FL-hTERT and 3xFLAG-tagged β-hTERT (hereby called HES2 ‘FL’ and 
HES2 ‘B’ for 3xFLAG-FL-hTERT and 3xFLAG-β-hTERT lines, respectively), enabling the 
use of commercially available anti-FLAG antibody to trace/isolate overexpressed FL-hTERT 
and β-hTERT transgenic proteins in hESCs (Fig. 2.1 A).   Briefly, endogenous FL-hTERT 
and β-hTERT transcripts were reverse-transcribed and PCR-amplified into library DNA 
sequence using hTERT specific primers (appendix A1: Table 2.1). The library hTERT 
sequences were extended to include Gateway LR-Clonase (ThermoFisher) adaptor sequences 
attL1 (5’GTACAAAAAAGCAGGCT), attL2 (TGGGTCGAAAGAACATG3’), 5’Kozak 
sequence (GCCGCCACC), 3xFLAG sequence 
(GACTACAAGGACCACGACGGTGACTACAAGGACCACGACATCGACTACAAGGA
CGACGACGACAAGTGA), and β-GEO drug resistance gene (appendix A1: Table 2.1) by 
PCR. The clone sequence of FL- and β-hTERT was ligated into the open reading frame of 
Tet-inducible/transposable entry vector of PiggyBac (PB) Transposon System (donated by 
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Nagy Lab, Mt Sinai Hospital). The correct orientation and sequence of ligated inserts was 
validated by DNA sequencing (Robarts Genomic facility). The entry vector plasmid and two 
other PB plasmid constructs containing PiggyBac rtTA gene (transactivator of gene of 
interest (GOI) expression; genome-integrated), and PiggyBac transposase gene (facilitates 
integration of GOI and rtTA into the genome; short-lived without genomic integration) were 
introduced to HES2 genome via electroporation (170V, 1050 µF). Successfully transformed 
HES2 cells were selected by blasticidin (10μg/ml; 1 day) and G418 (1mg/ml; 7 days).  The 
surviving cell clusters were single-celled and clonally picked to establish the final transgenic 
HES2 clones.  
 
2.1.4 Cell treatment scheme 
Preliminary experiments were carried out to determine the optimal treatment time and 
dose of doxycycline for the induction of hTERT transgene expression in HES2 clones 
(appendix A3: Fig 3.1). Non-transgenic HES2 (hereby referred to as HES2) and HES2 B and 
HES2 FL clones were treated with doxycycline-containing (1μg/ml) Essential 8 media for 2 
days. The culture medium was renewed daily. Based on studies that demonstrated extra-
nuclear localization of hTERT following oxidative stress treatments (H2O2 and/or high 
oxygen tension)[144, 174, 185], H2O2 (100μM)-containing growth medium was directly 
added to the culture 2 hours prior to cell harvest. Cells were kept under 2% oxygen tension 
for optimal cell growth of hESC (see section 1.1.2).  
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2.2 PCR protocols 
2.2.1 General Real-Time quantitative PCR protocol 
A phenol-chloroform extraction protocol was performed for RNA isolations as 
outlined in the product instructions (TRIzol reagent; ThermoFisher). Isolated RNA was 
reverse transcribed to cDNA using SuperScript III (ThermoFisher). cDNA concentrations 
were estimated with a NanoDrop (ThermoFisher) spectrophotometer and equal amount of 
template was ensured for each set of PCR reactions. RT-qPCR reactions consisted of 
SensiFASTTM (Bioline) PCR mix, gene-specific primer sets, and cDNA template. DNA 
polymerase was heat-activated at 95oC for 2 minutes prior to PCR cycles. Temperature 
cycling conditions were 95 oC for 10 seconds (denaturation), pre-determined temperature 
(primer specific; appendix A1: Table 2.1), 72oC for 30 seconds (elongation). HPRT1 was 
used as reference gene in all RT-qPCR experiments. Relative transcript quantity was 
determined based on ΔCt(gene of interest)ΔCt(HPRT1) values.  
 
2.2.2 Detection and quantitation of hTERT isoforms by Hydrolysis-probe assisted PCR 
TaqMan® Hydrolysis probe-assisted RT-qPCR was used to detect hTERT isoform 
transcripts.   Exon-exon junctions unique for each of hTERT isoforms (α+β+hTERT, α-
hTERT, β-hTERT, α-β-hTERT) were used as PCR priming sites (Fig. 2.1 B). α+β+hTERT 
are transcript species with α and β site intact, and includes FL-hTERT transcript. Importantly, 
the TaqMan primers are designed to detect any transcripts with the target junctions, meaning 
they do not distinguish between transcripts that are different outside of the PCR-amplified 
region (see Fig. 2.1 description). Additionally, the TaqMan primers do not distinguish 
recombinant 3xFLAG-hTERT transcript from endogenous hTERT transcript. FAM-
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conjugated DNA probes specific for the hTERT gene were employed to further increase the 
specificity and sensitivity of the RT-qPCR (Fig. 2.1 B). 1X TaqMan Universal PCR Master 
Mix (Applied Biosystems), 200nM forward and reverse primers, and 250nM hTERT specific 
FAM-probe were included per PCR reaction (20 μl). For reference, HPRT1 transcript 
abundance was measured alongside by SensiFAST PCR as outlined above. 
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Fig. 2.1 Transgene structure and TaqMan qPCR probe-/primer-binding sites. Dox-
inducible overexpression cassette for 3xFLAG-tagged FL-hTERT and 3xFLAG-tagged β-
hTERT were cloned and integrated into the genome of HES2 using the PiggyBac 
Transposon System (vectors donated by Nagy Lab, Mt Sinai Hospital; work of Dr. Jonathan 
H. Teichroeb). Two transgenes were genomically integrated A) PiggyBac rtTA gene for 
transactivator expression (required for transcription of 3xFLAG-hTERT) and DOX-
inducible 3xFLAG-tagged-hTERT expression sequence. B) Primers (black) and TaqManTM 
probe (red) annealing sites for hTERT variants. The primers cannot detect the differences 
in transcripts with alternatively spliced sites outside of the targeted regions. (i.e. 
α+β+hTERT primers will non-discriminately detect all transcripts with intact α and β 
sites regardless of alternative splicing that may be present outside of exon5/exon6 
junction-to-exon8/exon9 junction region). Moreover, the TaqMan primers do not 
differentiate between recombinant 3xFLAG-hTERT transcripts and endogenous hTERT 
transcripts. 
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2.2.3 RNA-immunoprecipitation and PCR-assisted detection of TERC  
1 x 107 HES2 transgenic clonal cells were trypsinized and lysed in cold non-
denaturing buffer (20mM Tris pH8.0, 137mM NaCl, 10% Glycerol, 1% IGEPAL (Sigma), 
2mM EDTA, 1X Protease Inhibitor Cocktail Set I (Calbiochem). The lysate was kept on ice 
for 30 minutes with constant agitation to help complete lysis. Cell debris was isolated and 
removed by centrifugation at 800g for 10 minutes. The cleared lysate was co-incubated with 
Anti-FLAG M2 Magnetic beads (30μl packed volume; Sigma), which was precleared with 
salmon sperm DNA (10 μg/ml) to prevent non-specific binding of nucleotides to the beads. 
The incubation was done at 4oC on a rotator overnight. Beads were washed 3 times with the 
lysis buffer and 2 times with TBE buffer (89mM Tris, 0.5mM EDTA, 89mM boric acid). 
TRIzol reagent (ThermoFisher) was added to the washed beads to extract bound RNA from 
3xFLAG-hTERT proteins. TERC transcript abundance was quantified and compared in 
doxycycline-negative and doxycycline-positive sample groups.  
 
2.2.4 PCR amplification of mitochondrial DNA for mitochondria DNA copy number 
A set of PCR primers (appendix A1: Table 2.1) targeting a small segment of 
mitochondrial DNA (tRNALeu) was used to estimate the relative mitochondrial DNA copy 
number in the sample groups (appendix A1: Table 2.1). A Mammalian Genomic DNA 
Miniprep Kit (Sigma) was used to extract genomic DNA. Nucleotide content in each sample 
was measured using a NanoDrop (ThermoFisher) spectrophotometer. Extracted gDNA was 
preheated to 75oC for 15 minutes to ease the supercoiling of circular mitochondrial DNA. 
The PCR reaction volume consisted of SensiFAST PCR master mix (5μl; Bioline), 10μM 
forward/reverse primers (0.2μl), 2μl template gDNA (6ng in mass), and 2.8μl RT-qPCR 
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grade water. PCR Cycling conditions were 95oC for 2mins (DNA polymerase activation; 
1cycle), 95oC for 10 seconds (denaturation), 62oC for 10 seconds (annealing), and 72 oC for 
20 seconds (synthesis). A single copy nuclear gene, beta-2-microglobulin (B2M) was used as 
a reference to normalize the data to the number of genomes per sample. 
 
2.3 Telomerase Activity Assay 
To confirm the telomerase activity of 3xFLAG-tagged transgenic hTERT, a telomeric 
repeat amplification protocol (TRAP) assay was performed as previously described [191]. 
HES2 and 3xFLAG-hTERT-expressing lines were treated with doxycycline (1μg/ml) for 2 
days. Cells were harvested by trypsinization and lysed in CHAPS lysis buffer (150mM KCl, 
50mM HEPES pH7.4, 0.1% CHAPS). RNaseOUTTM (Recombinant RNase Inhibitor; 
ThermoFisher) was included in the lysis buffer to prevent the degradation of TERC. To avoid 
protein degradation from freezing, all downstream steps were performed immediately and the 
samples were kept on ice. Total protein content in each sample was quantified by DCTM 
Protein Assay (BioRad). In the initial step of the tandem polymerase reactions, any TERC-
bound hTERT species in the lysate would elongate (by telomerase activity) the TS substrate 
primer (AATCCGTCGAGCAGAGTT) in vitro for 30 mins at 25oC. This was followed by 
heat-activation of DNA polymerase (SensiFAST; Bioline) and simultaneous heat-inactivation 
of hTERT protein at 95oC for 2 minutes. The de novo-synthesized telomeric sequences was 
amplified using a return primer ACX (GCGCGGCTTACCCTTACCCTTACCCTAACC). 
The temperature settings for this PCR (32 cycles; predetermined to ensure exponentially 
amplifying PCR cycle across all sample groups) were 95oC for 10 seconds (denaturation), 
58oC for 10 seconds (annealing), 72oC 30 seconds (elongation). An internal control primers 
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TSNT (AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT) and NT 
(ATCGCTTCTCGGCCTTTT) were included. TSNT is semi-competitively amplified by the 
annealing of TS primer and its dedicated return primer NT during PCR. The primary purpose 
of this is to rule out potential false-negative outcomes resulting from hindered DNA 
polymerase during PCR. Secondly, consistent amplification of TSNT amplicon (36bp) is 
indicative of equal PCR reaction efficiency. The finished PCR reaction mix was 
electrophoresed through a vertical native 12% polyacrylamide gel at 400V for 45 minutes in 
1X TBE buffer (89mM Tris, 0.5mM EDTA, 89mM boric acid) to resolve the product bands. 
The PAGE gel was stained with X1 SYBR Green I (ThermoFisher) nucleic acid dye in TBE 
for 30 minutes at room temperature. Bands were visualized using a Gel DocTM EZ (BioRad) 
and UV. The band intensity values of telomeric repeat products were first normalized to 
TSNT internal control band intensity.  
 
2.4 Immunodetection of 3xFLAG-hTERT isoforms 
2.4.1 Western Blot Analysis 
HES2 B6 and F12 clones (n≥3/group) were grown under feeder-free condition under 
2%O2 and H2O2 treatments. 3xFLAG-hTERT overexpression was induced by direct addition 
of doxycycline (1µg/ml) to the culture medium 48-hours prior to cell harvest.  Cells were 
lysed and fractionated using a mitochondria isolation kit per its instructions (Mitochondria 
Isolation Kit for Cultured Cells; ThermoFisher). Protease Inhibitor Cocktail Set I 
(Calbiochem) was added to all lysis/resuspension buffers to prevent protein degradation. The 
isolated mitochondria and nuclei of mitochondria-enriched, and nuclei-enriched samples 
were examined by Western Blot analysis with antibodies against voltage-dependent anion 
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channel (VDAC; mitochondria marker), Prohibitin (mitochondria marker), and histone H3 
(nuclear marker) (see appendix A2: Table 2.2). VDAC and histone H3 were used for 
normalization. 3xFLAG- hTERT in nuclear and mitochondrial fractions was traced using an 
anti-FLAG antibody (Sigma) and quantified by densitometry analysis using Image LabTM 
(BioRad). All membranes were developed using a VersaDoc Imaging System (BioRad) 
 
2.4.2 Immunocytochemistry  
For immunofluorescence microscopy, HES2 B6 and F12 clones were grown in 
feeder-free conditions on ChamberSlidesTM (Nunc), and were treated with H2O2 as 
previously indicated (see section 2.1.4). Cells were fixed and permeabilized in 4% 
formaldehyde (15 minutes) and in 0.25% TritonTM X-100 for (10 minutes), respectively. 
Cells were washed with phosphate buffered saline three times in between steps. Cells were 
blocked with 10% bovine serum albumin solution for 45 minutes at 37 oC. Cells were 
incubated with anti-TOM20 (1:500; rabbit polyclonal; ProteinTech) and anti-FLAG antibody 
(1:200; mouse monoclonal; Sigma) in 3% BSA solution overnight at 4oC. Lastly, cells were 
counterstained with NucBlue (nuclear stain; ThermoFisher). The subcellular localization of 
3xFLAG-hTERT was investigated by co-localization using a confocal microscope (Zeiss 
LSM 5 Duo Vario) and 63X oil-immersion objective lens. Image analysis software Zen 
(Zeiss) and Image J were utilized to analyze sample images. 
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2.4.3 Cell count analysis for intra-nuclear localization of 3xFLAG-hTERT isoforms 
HES2 B6 and F12 clones were grown in feeder-free condition on ChamberSlidesTM 
(Nunc) for 3 days until ~70% confluency was reached. Cells were treated with doxycycline-
containing (1μg/ml) Essential 8 media for 2 days. The culture medium was renewed daily. 
H2O2 was directly added to the media (100 μM final concentration) 2 hours prior to harvest. 
Field-of-view images of HES2 B6 (n=11) and HES2 FL (n=12) were taken as outlined in 
section 2.4.2. All images contained either a whole colony or a part of a colony. Only the clear 
and round nuclei (DAPI stain) were counted. Partial nuclei at the edge of the images were 
excluded from analysis. The intra-nuclear localization of 3xFLAG-β-hTERT and 3xFLAG-
FL-hTERT were categorized into an uniform distribution or a peripheral distribution (Fig. 
2.2). Nuclei with uniform distribution of 3xFLAG-hTERT was defined as nuclei with two or 
more nucleoli (dark and hollow space indicated by arrows in Fig. 2.2 left) as delineated by 
3xFLAG-hTERT signal (green). Nuclei with peripheral distribution of 3xFLAG-hTERT was 
defined as nuclei that has only one nucleolus two thirds of whose boundary is near the 
nuclear membrane (as delineated by DAPI stain; DAPI not shown in Fig. 2.2). Images were 
first assigned randomized numbers and alphabets by a third-party member.  The blinded 
images were presented to three volunteers from a third party in random order. Peripheral 
distribution was defined as an intra-nuclear distribution that exhibits only one nucleolus 
whose boundary is in close proximity with the nuclear boundary. (Fig. 2.2). Uniform 
distribution was defined as an intra-nuclear distribution that exhibits more than one 
nucleolus. The percentage of nuclei with peripheral distribution (out of total nuclei count) 
determined by the volunteers was averaged for statistical analysis. 
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Fig. 2.2: Representative confocal microscopy images of ‘uniform’ and ‘peripheral’ 
intra-nuclear distribution of 3xFLAG-FL-hTERT within nuclei.  The intranuclear 
distribution of 3xFLAG-FL-hTERT was visualized with anti-FLAG antibody and Alexa 
Fluor 488 secondary antibody (green). DAPI counter stain was used to mark nuclei. 
Nucleoli are indicated with white arrows. Scales bars (white) = 2 μm. 
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2.5 Flow Cytometry 
2.5.1 Mitochondria Membrane Potential 
The cyanine dye JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbo-
cyanine iodide; Sigma) [192, 193] is widely used for microscopic and cytometric estimation 
and measurement of mitochondrial membrane potential (Δψm). Aggregates of the dye (J-
aggregate) form at the high concentrations reached in energized mitochondria of cells 
exposed to near-micromolar external concentrations of the dye. J-aggregates are spectrally 
distinguishable from dye monomers. JC-1 is advantageous over other types of cationic Δψm 
dyes in that it selectively accumulates in mitochondria. JC-1 is excited at 488nm with the 
highest efficiency. When excited at 488 nm, JC-1 monomers emit green fluorescence with a 
maximum at 530 nm (green), whereas J-aggregates emit orange-red fluorescence with a 
maximum at 595 nm (orange-red). A subset of HES2, B6, and FL12 clones were treated with 
1µg/ml doxycycline for 2 days. All cells were treated with 100 µM H2O2 for 2 hours to 
induce oxidative/apoptotic stress. Thirty minutes prior to the harvest, cells were treated with 
JC-1 (10 µg/ml; dissolved in DMSO) for 30 minutes in the incubator. Cells were washed 
with PBS (Ca2+ free) once and collected by trypsinizing/centrifugation at 300g for 5 minutes. 
Cell pellets were re-suspended in flow-cytometry staining buffer (Ca2+ free PBS, 0.5% BSA). 
Spectral readings were taken immediately with BD AccuriTM C6 using a blue laser (488nm), 
bandpass filters FL2 (586±20nm; J-aggregate) and FL1 (530 ±15nm; JC-1 monomer). 
Twenty thousand events were recorded per group at all channels. 20μM Carbonyl cyanide 4-l 
(trifluoromethoxy) phenylhydrazone (FCCP; chemical dissipater of Δψm; Molecular 
Probes®)-treated samples were included as a positive control to represent a depolarized 
membrane. MMP variation was deduced by calculating FL2 (J-aggregate; high Δψm) to FL1 
ratio (JC-1 monomer; low Δψm). 
41 
 
 
 
2.5.2 Detection of apoptosis 
To assess the pro-survival effect of overexpressed 3xFLAG-hTERT in HES2, cells 
were stained with Annexin V-FITC (ThermoFisher)/7-amino-actinomycin (7-AAD; 
eBioscience), following 100 µM H2O2 treatment. Annexin V/7-AAD staining provides a way 
to discriminate between early apoptosis and late apoptosis. When a cell undergoes apoptotic 
cell death, phosphatidyl serine (PS; normally on the inner leaflet of plasma membrane) 
becomes exposed on the outer leaflet of the plasma membrane. Annexin V binds PS with 
high affinity and marks early-apoptotic cells. 7-AAD is a DNA intercalating dye that can 
enter dead cells with compromised membrane integrity. A subset of HES2, B6, and FL12 
clones were treated with 1µg/ml doxycycline for 2 days. All cells were treated with 100 µM 
H2O2 for 2 hours to induce oxidative/apoptotic stress. Following cell harvest by 
trypsinization/centrifugation (as outlined above), cells were re-suspended in Annexin V-
staining buffer (10mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) to 10
6 cells per/ml. 
Annexin V-FITC (15 minutes, at room temperature) and 7-AAD (5 minutes, at room 
temperature) were added to a 100 µl aliquot of the resuspension. Spectral readings were 
taken immediately with BD AccuriTM C6 using a blue laser (488nm), bandpass filters FL3 
(670 nm longpass; 7-AAD) and FL1 (530±15nm; FITC Annexin V-FITC). A total of 30000 
events were recorded per group at both channels.   
 
2.6 Statistical Analyses 
 All statistical analyses were performed using Prism 6 (Graph Pad Inc.), and are 
presented in mean ±SEM. An unpaired t-test was used for comparisons between DOX-treated 
and non-DOX-treated samples. Paired t-tests were used for flow cytometer analysis of DOX- 
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and non-DOX- groups. An One-Way ANOVA with Tukey’s post hoc test was used for 
analyses involving more than two hTERT isoforms or HES2 lines. Statistically significant 
data are indicated with asterisks (* for p<0.05, ** for p<0.01, *** for p<0.001). Non-
significant results were indicated with ‘NS’. 
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Chapter 3: Results 
3.1 Basic cell characterization of human embryonic stem cells 
3.1.1 Characterization of pluripotency markers in human embryonic stem cells 
Human embryonic stem cells (HES2 cell line) grow as flat and compact round 
colonies indicative of the primed pluripotent stem cell state [194] (Fig. 3.1 A).  Assessed by 
immunofluorescence microscopy, HES2 cells were positive for pluripotency markers SSEA-
4 and OCT-4, but negative for SSEA-1 (Fig. 3.1 C).  Transcripts of the α+β+TERT isoform 
(includes FL-hTERT transcript) and the most prominent hTERT splice variants (β-, α-, α-β-) 
were detected in HES2 cells that had been cultured under 21% oxygen tension (Fig. 3.1 B). 
Both β-hTERT and α+β+hTERT transcript levels were detected at about 40% of hTERT 
variant pool measured by TaqMan RT-qPCR (Fig. 2.1), and were significantly higher in 
abundance (~5-10 fold higher) than α-hTERT and α-β-hTERT transcript levels (Fig. 3.1 B). 
 
3.1.2 Characterization of hTERT isoforms in human embryonic stem cells 
HES2 cells were grown under 2% oxygen conditions, with and without doxycycline 
(DOX) and 100 μM H2O2 treatment to assess the potential side-effect of each treatment.  The 
percent (%) proportion of selected hTERT isoforms in each treatment group was investigated 
by TaqMan RT-qPCR (Fig. 2.1). When cells were grown under 2% oxygen, the transcript 
composition of α+β+hTERT and β-hTERT remained at approximately 40% and dominant 
over α-hTERT and α-β-hTERT (in comparison to when the cells grew in 21% oxygen; Fig. 
3.2 A and E). However, the splicing pattern changed when H2O2 or doxycycline was singly 
added to the culture media (Fig. 3.2 B and C). The proportion of β-hTERT transcript level 
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were increased in relation to α+β+hTERT and other isoforms when doxycycline and H2O2 
treatments were applied individually (Fig. 3.2 B and C). In case of doxycycline treatment, the 
percentage of α-β-hTERT transcript decreased slightly (statistical significance; Fig. 3.2 E). A 
similar decease in α-β-hTERT transcript levels were also observed when both H2O2 and 
doxycycline were applied in combination. Neither oxygen tension nor different combinations 
of doxycycline and H2O2 resulted in significant change in any hTERT isoform transcripts 
except in α-β-hTERT (Fig. 3.2 E).  Interestingly, the difference between % α+β+hTERT 
and % β-hTERT was not observed when DOX and H2O2 were applied simultaneously (Fig. 
3.2 D).  In all circumstances, β-hTERT was the most abundant hTERT transcript species 
expressed in the HES2 hESC line.  
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Fig. 3.1:  HES2 is a hESC cell line that expresses various markers of pluripotency and 
different proportions of endogenous telomerase reverse transcriptase (TERT) isoform 
transcripts.  A) HES2 (Non-transgenic) hESC colony grown on mitotically inactivated 
mouse embryonic fibroblast (MEF) feeder cells. Scale bar (white) = 200μm B) HES2 was 
cultured under ambient oxygen tension (~21% O2) and was harvested for RT-qPCR 
analyses. Primers specific for four different hTERT isoforms (α+β+, β-, α-, α-β-) were used 
to examine TERT isoform composition (n=4, error bars = ±SEM).  C) HES2 was cultured 
under 2% O2 in MEF-free environment to sub-confluency. Cells were fixed and assayed by 
immunofluorescence microscopy for OCT4, SSEA-4 (positive pluripotency markers), and 
SSEA-1 (negative pluripotency marker). Cells were counter-stained with DAPI. Scale Bars 
(white) = 25μm. NS = non-significant. 
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Fig. 3.2: Endogenous β-hTERT transcript is ubiquitously present at high levels in human 
embryonic cells grown under low oxygen tension conditions, with and without H
2
O
2
 and/or 
doxycycline (DOX) treatments. hESCs (HES2 cell line) were grown under low oxygen conditions 
(2% O
2
) with A) no treatment, B) 100μM H
2
O
2
, C) 1μg/ml DOX, D) 100μM H
2
O
2 
and 1μg/ml DOX, 
E) Combined representation of %hTERT isoform change under conditions specified in A-D. 
Endogenous hTERT variant transcript levels were examined by RT-qPCR (n=3, error bars = ±SEM). 
NS = non-significant.  
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3.2 Characterization of 3xFLAG-hTERT transgenic clones 
3.2.1 Characterization of 3xFLAG-hTERT transgene expression level in transgenic hESC 
clones 
DOX-induced 3xFLAG-hTERT isoform expression was examined in a broad panel of 
HES2 clones by Western blot analysis to select the number of lines for closer examination 
based on their transgene expression levels. Four HES2 clonal hESC lines overexpressing 
3xFLAG-ß-hTERT (B2, B3, B6, B7) and four HES2 clones overexpressing 3xFLAG-FL-
hTERT (FL7, FL9, FL10, FL12) were randomly chosen and analyzed for protein expression 
(appendix A3: Fig. 3.1). Based on the preliminary result of 3xFLAG-hTERT induction 12-
hours post doxycycline, the selection was further narrowed down to the least expressive β-
clone HES2 B3, the most expressive HES2 B6, a FL-clone with similar level of protein 
induction as B6 HES2 FL9, and the most expressive FL-clone HES2 FL12. HES2 B3 and 
HES2 B6 hESC lines exhibited the highest levels of 3xFLAG-β-hTERT transcripts.  HES2 
FL7 and HES2 FL12 hESC clonal cell lines were the least and the most expressive clones for 
3xFLAG-FL-hTERT, respectively (appendix A3: Fig 3.1). 3xFLAG-hTERT expression in 
the selected HES2 hESC clones (B3, B6, FL9, FL12) were examined more closely over a 
doxycycline time course via RT-qPCR (n=1) and Western blot analysis (Fig. 3.3). Clones B3 
and B6 had similar transgene expression at both the transcriptional and translation level. B3 
and B6 clones, however, showed much lower transgenic steady-state protein expression 
levels than FL9 and FL12 hESC clones. Of all, FL12 exhibited the highest FLAG-tagged 
protein levels at all DOX treatment times. Clone FL9 had markedly lower protein levels than 
the FL12 clonal hESC line (Fig.3.3 A and C). 
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3.2.2 Characterization of Pluripotency in HES2 B6 and HES2 FL12 hTERT cell lines 
 HES2 B6 and FL12 were treated with DOX (2 days; 1 μg/ml) and with H2O2 (final 4 hours; 
100μM) to assess the potential side effect of DOX and H2O2 treatment on pluripotency 
marker expression. Positive markers of pluripotency (OCT-4, SSEA-4) were present under all 
treatment conditions, while the negative marker of pluripotency (SSEA-1) remained absent 
(Fig. 3.4 and Fig. 3.5).   
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Fig. 3.3: RT-qPCR and Western blot analysis of doxycycline-induced expression of 3xFLAG-hTERT 
isoforms in HES2 clones over 3-day time course. HES2 clones (HES2 B3 and B6 for DOX-inducible 
3xFLAG-β-hTERT, and HES2 FL9 and FL12 for DOX-inducible 3xFLAG-FL-hTERT) were cultured under 
2% O
2
 and were treated with varying times (h = hours, d = days) of doxycycline (DOX) prior to harvest. A) 
In a pilot study, the abundance of various 3xFLAG-hTERT isoform transcripts was examined by RT-qPCR 
(n=1) B) Western blot using anti-FLAG antibody. C) Densitometry analysis was performed for quantification 
of the proteins. Data was normalized to β-actin (n=3, error bars = ±SEM). 
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Fig. 3.4: H2O2 and DOX treatments do not affect pluripotency marker expression in 
the 3xFLAG-β-hTERT transgenic HES2 B6 line. HES2 B6 (transgenic hESC line with 
DOX-inducible 3xFLAG-β-hTERT gene) was cultured in feeder free conditions under 2% 
O2. Cells were treated with or without DOX (2 days; 1 μg/ml) and H2O2 (4 hours; 100μM) 
prior to fixation. Cells were stained for positive markers of pluripotency (OCT4 & SSEA-
4; green fluorescence) and a negative marker of pluripotency (SSEA-1). DAPI (blue 
fluorescence) was used as counterstain and representative DAPI images are only shown for 
the first treatment group (-H2O2, -DOX). Scale bars = 60μm. 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5: H2O2 and DOX treatments do not affect pluripotency of the 3xFLAG-FL-
hTERT transgenic HES2 FL12 lines. HES2 FL12 (transgenic hESC line with DOX-
inducible 3xFLAG-FL-hTERT gene) were cultured in feeder free condition under 2% O2. 
Cells were treated with or without DOX (2 days; 1 μg/ml) and H2O2 (4 hours; 100μM) prior 
to fixation. Cells were stained for positive markers of pluripotency (OCT4 & SSEA-4; green 
fluorescence) and a negative marker of pluripotency (SSEA-1). DAPI (blue florescence) 
was used as counterstain and representative DAPI images are only shown for the first 
treatment group (-H2O2,-DOX). Scale bars = 60μm. 
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3.3 Characterization of DOX-induced recombinant hTERT in HES2 B6 and 
HES2 FL12 
 
3.3.1 Endogenous TERC-binding of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT subunits 
          RNA-immunoprecipitation (RIP) using a FLAG antibody was performed to determine 
whether the 3xFLAG-hTERT transgenic proteins have the ability to bind to the telomerase 
RNA-component (TERC). TERC recovery from the RIP eluents of DOX-treated samples and 
non-DOX-treated samples were compared. Overexpression of 3xFLAG-hTERT by 
doxycycline prior to RIP resulted in approximately 60-fold increase in TERC recovery for 
3xFLAG-FL-hTERT, and 10-fold increase for 3xFLAG-β-hTERT (Fig. 3.6 A, B, C). 
Doxycycline-treated HES2 (non-transgenic; negative control) did not result in any change in 
TERC recovery, and resulted in a very low TERC PCR-amplification (Fig. 3.6 D). 
3.3.2 Endogenous RMRP-binding of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT subunits 
          Another RIP using a FLAG antibody was performed to determine whether the 
3xFLAG-hTERT transgenic proteins have the ability to bind to the RNA component of 
RNase MRP (RMRP).  Overexpression of 3xFLAG-hTERT by doxycycline prior to RIP 
resulted in an approximately 4-fold increase in RMRP recovery for 3xFLAG-FL-hTERT, and 
a 2-fold increase for 3xFLAG-β-hTERT (Fig. 3.7 A, B, C).  RMRP recovery from DOX-
treated HES2 (non-transgenic; negative control) was not different from its control. Notably, 
the amount of PCR-amplified RMRP from HES2 control group (Fig. 3.7 D) was significant 
and was comparable to that from 3xFLAG-β-hTERT RNA immuoprecipitates (Fig. 3.7 B). 
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3.3.3 Telomerase activity in HES2 B6 and HES2 FL12 hESCs 
         The effect of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT overexpression on total 
telomerase activity of HES2 B6 and FL12 cell lines was investigated by the telomerase 
repeat amplification protocol (TRAP) assay (Fig. 3.8). Negative controls (heat-inactivated 
lysate and no-lysate control) did not generate any product bands (Fig.3.8 A). Doxycycline in 
non-transgenic HES2 had no effect on the endogenous telomerase activity (Fig. 3.8 B top). 
DOX-induction of recombinant β-hTERT in HES2 B6 resulted in ~30% decrease in the total 
telomerase activity, whereas DOX-induction of recombinant FL-hTERT in HES2 FL12 had 
no effect (Fig. 3.8 B bottom left and right, respectively). 
3.3.4 Re-visiting DOX-induction of 3xFLAG-hTERT transcription in HES2 clones 
          Since overexpression of 3xFLAG-FL-hTERT did not result in an the expected increase 
in telomerase activity in HES2 FL12 (Fig. 3.8 B), we re-investigated the 3xFLAG-hTERT 
transgene expressions and endogenous hTERT isoform transcript abundance in the trangenic 
HES2 clones.  The transcript level of different hTERT isoforms in HES2 FL12 and HES2 B6 
was examined after DOX-induction by hydrolysis-probe-assisted RT-qPCR. The addition of 
DOX in HES2 FL12 resulted in ~500-fold increase in FL-hTERT transcript, but suprisingly a 
~300-fold increase in β-hTERT transcript, and ~200-fold increase in α-β-hTERT transcript 
was also observed compared to non-induced controls (Fig.3.9 A). Interestingly, the HES2 B6 
cell line expressed only the β-deletion-containing TERT isoforms upon doxycycline 
treatment. β-hTERT abundance rose sharply (~1000-fold in comparison with its non-induced 
control) after doxycycline treatment in HES2 B6. A ~150-fold increase in α-β-hTERT was 
also observed (Fig.3.9 B). 
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Fig. 3.6: Doxycycline-induced transgenic telomerase proteins (3xFLAG-β-hTERT and 
3xFLAG-FL-hTERT) bind to the telomerase RNA component (TERC). Cells were 
grown under 2% O
2
 and were treated with 1μg/ml doxycycline (DOX) for two days prior to 
harvest. DOX-induced 3xFLAG-hTERT isoforms were isolated from their respective clones 
by immunoprecipitation using anti-FLAG-magnetic beads. Eluted proteins were 
subsequently denatured to release any bound RNA for downstream RT-qPCR analysis. A) 
Comparison of results in HES2 transgenic lines, and individual TERC enrichment data from 
B) HES2 B6 C) HES2 FL12 D) Non-transgenic HES2 control (n=3, error bar=±SEM, 
**=P<0.01, ***= P<0.001).  
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Fig. 3.7:  Enrichment of RNA component of mitochondrial RNA processing 
endoribonuclease (RMRP by doxycycline-induced transgenic telomerase proteins 
(3xFLAG-β-hTERT and 3xFLAG-FL-hTERT). Cells were grown under 2% O
2
 and 
were treated with 1μg/ml doxycycline (DOX) for two days prior to harvest. DOX-induced 
3XFLAG-hTERT isoforms were isolated from their respective clones by 
immunoprecipitation using anti-FLAG-magnetic beads. Eluted proteins were subsequently 
denatured to release any bound RNA for downstream RT-qPCR analysis. A) Comparison 
of results in HES2 transgenic lines, and individual RMRP enrichment data from B) HES2 
B6 C) HES2 FL12 D) Non-transgenic HES2 control (n=3, error bar = ±SEM).  
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Fig. 3.8: Altered telomerase activity levels in doxycycline (DOX)-induced transgenic 
telomerase proteins (3xFLAG-hTERT) in hESCs. Cells were grown under 2% O
2
 and were 
treated with 1μg/ml doxycycline for two days prior to harvest. A) Representative DNA gel of 
telomerase-repeat amplification assay by qPCR. Relative telomerase activity between samples is 
reflected in the intensity and the range of telomerase product bands. H.I. = Heat-Inactivated B) Band 
intensity of amplified telomerase product was measured by densitometry analysis and represented 
as relative telomerase activity. Data were normalized to internal control band intensities (n=4, error 
bar=±SEM).  
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Fig. 3.9: DOX-induction of 3xFLAG-hTERT isoforms results in a simultaneous 
increase in the amount of other hTERT transcript variants containing β-deletion. A) 
HES2 FL12 and B) B6 were grown under 2% O2 and were treated with 1μg/ml doxycycline 
for two days prior to harvest. hTERT variant transcript abundance in each sample was 
examined by RT-qPCR using primer sets specific for α+β+, α-, β-, α-β-. The primers do not 
discriminate endogenous hTERT species from transgenic hTERT species. n=3, error bars = 
±SEM. 
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3.4 3xFLAG-hTERT localization under H2O2-induced oxidative stress 
3.4.1 Sub-cellular Western Blot Analysis of 3xFLAG-FL-hTERT and 3xFLAG-β-hTERT 
expressing hESC lines 
H2O2 (100µM) was applied to promote mitochondrial localization of 3xFLAG-β-
hTERT and 3xFLAG-FL-hTERT in the respective transgenic cell lines. Cells were 
fractionated into nuclear fraction and mitochondrial fraction for protein analysis. Western 
blot analysis of sub-cellular fractions demonstrated that the level of mitochondrial 3xFLAG-
β-hTERT appears to increase with 1h H2O2 (100µM) treatment, but fluctuates with longer 
H2O2 exposure (Fig. 3.10 Column A). However, no statistical significance (p>0.05) was 
observed between different treatment groups.  Similarly, 3xFLAG-FL-hTERT levels in the 
mitochondrial fraction initially increased at 30-minute post H2O2 (100µM) treatment, but 
decreased over longer exposure time (Fig. 3.11 Column A).  Again, no statistical significance 
(p>0.05) was detected between different treatment groups.  Similarly, neither the levels of 
3xFLAG-β-hTERT nor 3xFLAG-FL-hTERT changed significantly in the nuclear fractions 
over the H2O2 treatment time course (Fig. 3.10 B and Fig. 3.11 B). Additionally, I failed to 
observe significant intra-cellular movement of 3xFLAG-hTERT when I performed the same 
fractionation experiment using prohibitin as a mitochondrial marker (appendix A4: Fig. 3.2).  
3.4.2 Immunocytochemistry and Image analysis of 3xFLAG-FL-hTERT and 3xFLAG-β-
hTERT localization in hESCs 
Due to the inconclusive results obtained by the cellular fractionation studies, I 
monitored 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT cellular localization by 
immunofluorescence microscopy.  I failed to see co-localized signal from MitoTracker 
(mitochondria) and M2-anti-FLAG/Alexa Fluor 488 (3xFLAG-hTERT) in either HES2 
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transgenic clones (Fig. 3.12). Much of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT 
remained in nuclei regardless of different durations of H2O2 exposure (Fig. 3.12). Such 
nuclear localization of 3xFLAG-FL-hTERT persisted even when HES2 FL12 cells were 
exposed to 21% O2 for 3 days (appendix A5: Fig.3.3). Interestingly, there appeared to be 
distinct patterns of 3xFLAG-hTERT species’ distribution within the nuclei. Most cells 
exhibited ‘uniform’ intra-nuclear distribution of 3xFLAG-hTERT (indicated by the red arrow 
in Fig. 3.12). Some nuclei exhibited ‘peripheral’ intra-nuclear distribution of 3xFLAG-
hTERT (indicated by the white arrow in Fig. 3.12). The number of cells exhibiting the 
different intra-nuclear distributions of 3xFLAG-hTERT was counted from 
immunofluorescence images. However, the addition of doxycycline to HES2 B6 (Fig. 3.13 
A) and HES2 FL12 (Fig. 3.13 B) resulted in no significant change in the intra-nuclear 
localization of 3xFLAG-hTERT. 
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Fig. 3.10: H2O2-induced Oxidative stress and its effect on the cellular localization of 
3xFLAG-β-hTERT. Cells were grown under 2% O2 and were treated with 1μg/ml DOX 
for two days prior to harvest. 100μM H2O2 was applied at different times (30m, 1hr, 2hr) 
prior to harvest. Nuclei-enriched fraction was isolated via fractionation by differential 
centrifugation. The amount of 3xFLAG-hTERT species in respective sample groups were 
investigated by Western blot/densitometry analysis. Results were normalized to VDAC and 
Histone H3 for mitochondrial and nuclear fractions, respectively. Densitometry results of 
treatment groups are relative to H2O2 negative control. Western Blot and densitometry 
analysis plots of A) mitochondrial fraction and B) nuclear fraction. n=3, error bar=±SEM. 
NS = non-significant 
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Fig. 3.11: H2O2-induced Oxidative stress and its effect on the cellular localization of 
3xFLAG-FL-hTERT. Cells were grown under 2% O2 and were treated with 1μg/ml DOX 
for two days prior to harvest. 100μM H2O2 was applied at different times (30m, 1hr, 2hr) 
prior to harvest. Nuclei-enriched fraction was isolated via fractionation by differential 
centrifugation. The amount of 3xFLAG-hTERT species in respective sample groups were 
investigated by Western blot/densitometry analysis. Results were normalized to VDAC and 
Histone H3 for mitochondrial and nuclear fractions, respectively. Densitometry results of 
treatment groups are relative to H2O2 negative control. Western Blot and densitometry 
analysis plots of A) mitochondrial fraction and B) nuclear fraction. n=3, error bar=±SEM. 
NS = non-significant 
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Fig. 3.12: H2O2-induced effect on the intra-cellular localization of 3xFLAG-β-hTERT 
and 3xFLAG-FL-hTERT in hESCs. Transgenic hESCs were grown under 2% O2 and 
transgenes induced by treated with 1μg/ml DOX for two days prior to harvest. 100μM H2O2 
was applied at different durations (1hr, 2hr) prior to fixation. Immunofluorescence-
microscopy images of 3xFLAG-hTERT (green fluorescence), mitochondria (MitoTracker; 
red fluorescence), and nuclei (DAPI; blue fluorescence) in HES2 transgenic clones. Images 
were taken using a confocal microscope (63X oil-immersion objective lens, x10 eyepiece 
lens). 3xFLAG-hTERT were predominantly nuclear, and exhibited either peripheral 
localization (white arrow; upper row second column) or more uniform distribution within 
nuclei (red arrow). Scale bar = 20 µm. 
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Fig. 3.13: Microscopic analysis of intra-nuclear localization of 3xFLAG-β-hTERT 
and 3xFLAG-FL-hTERT under H2O2-induced oxidative stress. Multiple confocal 
images of HES2 B6 and HES2 FL12 (see Fig. 3.12) were taken and blinded.  Percentages 
of cells that exhibited peripheral 3xFLAG-hTERT localization was counted and averaged 
by three volunteers. Only the whole and fully visible cells (nuclei) were taken into 
account. A) 3xFLAG-β-hTERT (n=11) B) 3xFLAG-FL-hTERT (n=12). Error bars ±SEM 
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3.5 The effect of overexpressed 3xFLAG-hTERT on mitochondrial function 
3.5.1 The effect of DOX-induced 3xFLAG-hTERT on mitochondria membrane potential 
 It was previously shown that ectopic expression of FL-hTERT augments mitochondria 
membrane potential in human embryonic lung fibroblast cells [195].  Human embryonic stem 
cells (HES2 cell line) were stained with JC-1 dye, which accumulates within the 
mitochondria and varies its fluorescence excitation in an MMP-dependent manner.  The 
results were examined and analyzed by flow cytometry (Fig. 3.14). Both 3xFLAG-β-hTERT 
and 3xFLAG-FL-hTERT overexpression in hESCs appeared to slightly decrease MMP 
activity (2nd and 3rd bars) compared to the doxycycline control group in non-transgenic HES2 
cells (1st bar) (Fig. 3.15). However, no significant change in MMP was observed for either 
transgenic clones.  
 
3.5.2 The effect of DOX-induced 3xFLAG-hTERT on mitochondrial DNA copy number 
 A previous report has shown that ectopically expressed hTERT results in decreased 
mitochondrial DNA copy number in human embryonic lung fibroblast cells under 21% 
oxygen tension [195]. The relative mitochondrial DNA copy number was compared in HES2 
B6 and HES2 FL12 clones before and after DOX-induction of 3xFLAG-hTERT species. 
Approximately a 20% decrease (statistically significant) in mitochondrial DNA copy number 
was observed when HES2 cells were treated with doxycycline (Fig. 3.16 A). Interestingly, 
doxycycline treatment of HES2 B6 and HES2 FL12 cells resulted in neither reduction nor 
increase of mitochondrial DNA copy number (Fig. 3.16 B and C).  
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3.5.3 The effect of DOX-induced 3xFLAG-hTERT on mitochondria biogenesis and function 
 Mitochondria biogenesis is regulated by several nuclear genes. A panel of markers for 
mitochondria biogenesis was monitored by RT-qPCR after doxycycline treatment in HES2 
clonal lines (Fig. 3. 17).  No significant change in steady-state transcript abundance was 
observed for any of the examined genes.  Notably, POLG (mitochondrial DNA polymerase 
subunit) did not change with doxycycline treatment in any of the HES2 lines (Fig. 3.17 first 
bar plot).  SOD2 (mitochondrial anti-oxidant defense enzyme) and UCP2 (potent 
mitochondria uncoupler protein) expression levels were also estimated by RT-qPCR.  In 
agreement with previous literatures, UCP2 transcript was highly abundant in comparison to 
the biomarkers of mitochondria biogenesis (Figs. 3.17 and 3.18). No significant change was 
observed with either of these genes following doxycycline treatment. 
 
 
 
 
 
 
 
 
 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.14: Mitochondrial membrane potential (MMP) gating strategy and 
controls for flow cytometry experiment with JC-1 dye measurements. 3xFLAG-
hTERT isoform expression was induced via 1μg/ml DOX (2 days) in HES2 B6 and 
HES2 FL12. Cells were grown under 2% O2 and were stained with JC-1 dye for 30 
minutes. Control groups were no JC-1 control, 20μM FCCP (chemical uncoupler of 
mitochondria electron transport chain). Mean fluorescence from FL1 and FL2-
positive populations were measured for FL2:FL1 ratio calculation. Cell debris was 
excluded from analysis. Gated-events (15,000) were recorded and analyzed. 
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Fig. 3.15: 3xFLAG-β-hTERT and 3xFLAG-Full-Length-hTERT do not affect 
mitochondrial membrane potential (MMP) in hESCs. Gated mean fluorescence ratio of 
J-aggregate (FL2; orange-red; bandpass filter 586 ± 20nM) to monomer (FL1; green; 
bandpass filter 530 ± 15nM) was measured and calculated by flow cytometry. The fold 
change in FL2:FL1 ratio before and after the addition of doxycycline in HES2, HES2 FL12, 
HES2 B6 is shown as a bar plot. n=4, error bars = ±SEM, NS = non-significant. 
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Fig. 3.16: Doxycycline affects mitochondria copy number in hESCs. 3xFLAG-hTERT isoform 
expression was induced via 1μg/ml DOX (2 days) in HES2 B6 and HES2 FL12 clonal cell lines. 
HES2 (nontransgenic) was also treated with doxycycline (as drug control). All cells were grown 
under 2% O
2
 tension. The mitochondria DNA copy number was estimated by PCR-amplifying a 
small segment of mitochondria DNA. Results were normalized to B2M (a single copy nuclear gene). 
A) HES2 B) HES2 B6 C) HES2 FL12 (n=3, error bars = ±SEM). 
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Fig. 3.17: The effect of 3xFLAG-β-hTERT and 3xFLAG-Full-Length-hTERT 
overexpression on mitochondria biogenesis regulator gene expression. The transcript 
levels of mitochondria biogenesis regulators were examined by RT-qPCR. HES2, HES2 B6, 
HES2 FL12 clonal hESC lines were treated with 1μg/ml DOX for 2 days prior to analysis. 
n=3, error bars = ±SEM 
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Fig. 3.18:  Dox-induced 3xFLAG-β-hTERT and 3xFLAG-Full-Length-hTERT 
overexpression does not affect UCP2 and SOD2 transcript abundance levels. The 
transcript levels of SOD2 (antioxidant enzyme) and UCP2 (endogenous mitochondrial 
uncoupler) were examined via RT-qPCR. HES2, HES2 B6, HES2 FL12 clonal hESC lines 
were treated with 1μg/ml DOX for 2 days prior to analysis (n=3, error bars = ±SEM). 
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3.6 The effect of doxycycline-induced 3xFLAG-hTERT on cell survival in HES2 
lines under H2O2-induced oxidative stress 
 
 Cell viability, apoptosis, and cell death were measured by flow cytometry. Viable, 
apoptotic, and dead cell groups were defined as annexin V-FITC-/7-AAD-, annexin V-
FITC+/7-AAD-, and 7-AAD+ populations, respectively. (Fig. 3.19). Doxycycline treatment in 
HES2 resulted in no change in the assessed cell populations (Fig. 3.20 A, Fig. 3.21 A, and 
Fig. 3.22 A). The percent viability of HES2 B6 decreased by ~5% following DOX-induction 
(Fig. 3.20 B). At the same time, the percent apoptotic population of HES2 B6 increased by 
~5% following DOX treatment, but the percent dead cell population was unaffected (Fig. 
3.21 B and Fig. 3.22B). Conversely, the percent viability increased by ~14% with DOX-
treatment in HES2 FL12 (Fig. 3.20 C). This was concurrent with a ~19% decrease in the 
apoptotic population, and a ~5% increase in the dead cell population in HES FL12 cells (Fig. 
3.21 C and Fig. 3.22 C). 
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Fig. 3.19: Representative plots showing stain controls and gating strategies for 
flowcytometry experiment with 7-AAD and Annexin V for measuring cell death upon 
H2O2 treatment.  3xFLAG-hTERT isoform expression was induced via 1μg/ml DOX (2 
days). Cells were grown under 2% O2 and 100μM H2O2 was added the growth medium 2-
hour prior harvest. Cells were stained with annexin V-FITC and 7-AAD to label apoptotic 
and dead cells, respectively. Measured cell population was first gated to exclude cell debris 
and background signals. Q1-UR: +Annexin V/+7-AAD (dead), Q1-UL: -Annexin V/+7-
AAD(dead), Q1-LR: +Annexin V/-7-AAD (apoptotic), Q1-LL: -Annexin V/-7-AAD 
(viable). 
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Fig. 3.20: Effect of DOX-induced 3xFLAG-β-hTERT and 3xFLAG-Full-Length-
hTERT on cell viability in HES2 under H2O2-induced cell stress. Percent viable cell 
(Annexin V-FITC/7-AAD negative) plots in A) HES2, B) HES2 B6 C) HES2 FL12 (n=4, 
error bars = ±SEM). 
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Fig. 3.21: Effect of DOX-induced 3xFLAG-β-hTERT and 3xFLAG-Full-Length-
hTERT on apoptosis in HES2 under H2O2-induced cell stress. Percent apoptotic cell 
(Annexin V-FITC positive/7-AAD negative) plots in A) HES2, B) HES2 B6 C) HES2 FL12 
(n=4, error bars = ±SEM). 
75 
 
 
 
 
 
 
 
 
 
Fig. 3.22: Effect of DOX-induced 3xFLAG-β-hTERT and 3xFLAG-Full-Length-
hTERT on cell death in HES2 under H2O2-induced cell stress. Percent dead cell 
(Annexin V-FITC/7-AAD positive) plots in A) HES2, B) HES2 B6 C) HES2 FL12 (n=4, 
error bars = ±SEM). 
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Chapter 4: Discussion 
The telomerase RNP complex plays a crucial role in maintaining telomere 
homeostasis. To enable rapid and indefinite cellular proliferation, cancer cell utilizes 
telomere-lengthening cellular machinery such as alternative lengthening of telomere (ALT) 
or telomerase. Several studies in human cancer and fibroblast cells have pointed to extra-
nuclear translocation of telomerase catalytic subunit hTERT and its significance in extra-
telomeric functions in modulating cellular behavior. Notably, alternative splicing of the 
TERT transcript to β-hTERT and its extra-nuclear localization have been previously reported 
in a subset of cancer cells. hESCs and cancer cells share similar cell physiology including 
high proliferative capacity, glycolysis-dependent energy metabolism, and high telomerase 
expression. In light of recent discoveries of hTERT’s mitochondrial roles, I hypothesized that 
extra-nuclear translocation of FL-hTERT and β-hTERT will occur in hESC, and that they 
will collect at mitochondria under hydrogen peroxide-induced oxidative stress, thereby 
modulating mitochondrial functions. Owing to the lack of hTERT-specific antibody and the 
intricacy of hTERT alternative splicing, hTERT-overexpressing cell lines (doxycycline-
inducible) were established by PiggyBac genomic integration of Flag-tagged (N-terminal) 
FL-hTERT and Flag-tagged β-hTERT mRNA sequences (see section 2.1.3). Various effects 
of doxycycline-induced hTERT expression were assessed in the clonal hESCs while paying 
extra-attention to the potential side effects of doxycycline and the Flag-fusion at the N-
terminal of the TERT transgene. 
4.1 Pluripotency and alternative splicing of endogenous hTERT in hESC 
Prior to the overexpression studies, I began by verifying the pluripotent state of the 
hESC line HES2, cultured under 21% oxygen, by immunofluorescence microscopy. HES2 
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cells were marked immuno-positive for OCT4 and SSEA-4, and negative for SSEA-1 (Fig. 
3.1 C) supporting their pluripotent state.  
TaqMan RT-qPCR was used to detect endogenous hTERT transcripts isoforms 
containing neither α- nor β-deletion (α+β+hTERT), β-deletion (β-hTERT), α-deletion (α-
hTERT), and both α- and β-deletion (α-β-hTERT). Importantly, each of the four primer sets 
(α+β+, β-, α-, α-) used for the PCR detects the presence of only the respective deletion, but 
does not distinguish between any other insertions/deletions that may be present on the same 
target transcript. For example, α+β+hTERT, as detected by TaqMan primers and probe, 
includes not only the full-length-(FL-)hTERT transcript but also α+β+ transcript species with 
other deletions/insertions present elsewhere. To increase the specificity of detection, one 
could employ long-range PCR to amplify the whole lengths of hTERT transcripts. 
My PCR results revealed that HES2 was indeed expressing certain hTERT isoforms 
exhibiting different combinations of α- and β-deletion when cultured under 21% oxygen. The 
transcript abundance of β-hTERT was proportionately the highest among α+β+, β-, α-, α-β-
hTERT transcripts, and was as high as that of α+β+hTERT (Fig. 3.1 B). In a previous study 
by Ulaner et al. [78, 102], it was demonstrated that the splicing pattern of hTERT was 
tissue-, and developmental-stage-specific. In human embryonic kidney tissue, β-splicing 
occurs at the expense of FL-hTERT transcript, and this was proposed to be a mechanism 
involved in downregulation of telomerase activity. Similarly, Yan and colleagues [111] 
demonstrated a negative correlation of telomerase activity with the constituent ratio of 
deletion hTERT variants, especially β- hTERT. In hESCs, telomere length homeostasis is 
strictly maintained as excessively long telomeres can cause telomere instability and 
replication stress [196]. Therefore, it is highly possible that a similar regulation of telomerase 
activity by alternative splicing may be reinforced in hESC to prevent excessive lengthening 
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of telomeres. Notably, β-hTERT transcript persisted in human fetal kidney development even 
in the absence of all other hTERT isoforms (including the FL-hTERT), raising the possibility 
of β-hTERT’s involvement outside canonical telomerase function. 
I then examined how the splicing of endogenous hTERT changed when cells were 
cultured with 2% oxygen and different combinations of doxycycline and H2O2 (Fig. 3.2). 
When cells were cultured under 2% oxygen, the transcript composition of α+β+hTERT and 
β-hTERT remained nearly equal in quantity and higher than that of α-hTERT and α-β-
hTERT compared to when the cells were cultured in 21% oxygen (Fig. 3.2 A and E). In 
contrast, our lab’s previous work in H9 hESC line showed that α+β+hTERT and α-hTERT 
transcripts dramatically decreased going from 21% O2 to 2% O2 culture condition [184]. 
Radan et al. proposed that the change in splicing pattern might be attributed to the function of 
hypoxia-inducible-factor (HIF), based on its ability to regulate alternative splicing in hypoxic 
conditions [209 - 213]. The apparent discrepancy in our results may arise from cell line-
specific differences and/or from the differences in our methodology. Although all hESC lines 
share the expression of characteristic pluripotency markers, they exhibit several differences 
owing to the wide range of factors such as variable culture conditions and the inherent 
genetic variation of the embryos from which embryonic stem cells were derived [199]. Thus, 
it is possible that the two cell lines used in this study (HES2) and by Radan et al. (H9) 
respond differently to the changing oxygen tension. Secondly, the outcome of the result may 
have greatly depended on the oxygen tension the cells were exposed to during maintenance 
prior to the hypoxic/normoxia treatment. Lastly, the duration of hypoxia and normoxia 
treatment varied between the two studies (5 days in the study by Radan et al. and 3 days for 
the current thesis). It would be interesting to see whether the alternative splicing patterns 
converge when the experimental differences are removed. 
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The splicing pattern changed when H2O2 or doxycycline was singly added to the 
culture media (Fig. 3.2 B and C). After 2-hour treatment of 100 μM H2O2, the percent 
transcript composition of β-hTERT was significantly higher than that of α+β+hTERT (Fig. 
3.2 B). It appeared that the increased β-splicing came at the expense of α+β+splicing. 
However, no statistically significant change was seen with any of the four hTERT isoforms 
between control group (2% oxygen) and H2O2-treated group. A small sample size (n=3) may 
be preventing the observation of a statistically true event. Nonetheless, it appears evident that 
H2O2 alters the splicing pattern of hTERT in favor of β-hTERT. Other studies have shown a 
similar effect of H2O2 on alternative splicing of different genes through oxidative stress [212, 
213] and mitochondrial damage [202]. Gilbert et al.[201] demonstrated that H2O2 directly 
affects the protein abundance of spliceosome complex proteins (hnRNPs, PTBP1), which 
suggests H2O2 can potentially alter the transcript splicing of many genes and, perhaps, 
hTERT. H2O2 is a cell membrane-permeable molecule that is naturally generated as 
byproduct of aerobic respiration [203], and can act as inter- and intra-cellular signaling 
molecule [204]. In a pathological context, H2O2 concentration greater than 50μM is generally 
considered cytotoxic, but this is largely cell-type and culture media-dependent as different 
cells possess differential resistance to oxidative stress [205, 206]. In mESC, 24 hour 150μM 
H2O2 treatment results in apoptosis, whereas shorter treatment time (2 hours, same 
concentration) resulted in transient cell cycle arrest [207]. Research conducted by Kumar et 
al. [208] demonstrated that treating hESC with 200 μM H2O2 for 30 minutes resulted in a 
significant increase in DNA damage. The concentration of H2O2 used in my study, 100μM, 
albeit lower than 200μM, was applied for much longer duration (two hours) than 30 minutes, 
and may have caused significant amount of DNA damage in the cells, triggering cell stress- 
and apoptotic signaling cascades. H2O2, in fact, is a poorly reactive molecule and undergoes 
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Fenton-reaction with intra-cellular iron (Fe2+) to become the deleterious hydroxyl radical 
[209]. Intriguingly, Santos et al. [172] showed that ectopically expressed FL-hTERT in 
normal human fibroblasts cells promotes H2O2-induced mitochondrial DNA damage by 
increasing bioavailability of divalent iron pool. Therefore, it is possible that the observed 
shift towards β-splicing may have been a rescue attempt to lessen the damage-amplifying 
effect of FL-hTERT.  
Similarly, 2-day treatment of 1μg/ml doxycycline resulted in higher percent 
composition of β-hTERT transcript relative to that of α+β+hTERT (Fig. 3.2 C). This result 
indicates that doxycycline treatment has a side-effect on the splicing pattern of hTERT (and 
possibly other pre-mRNA transcripts) in hESCs. Whether doxycycline acts directly or 
indirectly on the splicing machinery of hTERT is unclear at this stage. Doxycycline is 
categorized as a tetracycline family antibiotic that is used to cure a broad spectrum of 
bacterial infections [209 – 211]. The antibacterial activity by tetracyclines is mediated by 
inhibiting the bacterial ribosome, effectively blocking bacterial protein synthesis [210]. 
Despite its frequent use in inducible mammalian transgene systems, significant evidence 
exists to show that tetracyclines can impair mitochondrial function in eukaryotic cells 
through the inhibition of mitochondrial ribosome, which may be explained by the stark 
similarity of bacterial ribosomes and eukaryotic mitochondrial ribosomes (in support of 
endosymbiotic bacterial origin of mitochondria) [212 - 215]. The effect of doxycycline 
extends to hESC and iPSC. Work by Chang et al. [216] showed that doxycycline improves 
viability and self-renewal of hESCs and iPSCs through activation of PI3K/AKT signaling, an 
important pathway for self-renewal of PSCs (see section 1.1.1). However, it is not known 
whether the activation of PI3K/AKT signaling is a result of mitochondrial inhibition by 
doxycycline. The PI3K/AKT signaling pathway controls numerous cellular processes such as 
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glucose metabolism, protein synthesis, and RNA processing. AKT can influence splicing 
regulation indirectly by phosphorylating serine/threonine-protein kinase 2 (SRPK2) and 
serine/threonine-protein kinase 1 (SRPK1; auto-phosphorylation), which in turn activates SR 
family proteins [217, 218]. Alternatively, AKT can directly phosphorylate SRSF1, SRSF7 
and SRSF5 [219-221]. Considering β-deletion is also mediated by a SRSF family protein 
(SRSF11; see section 1.2.2), it is likely the case that doxycycline treatment acts on the 
splicing machinery of hTERT by first activating the PI3K/AKT signaling pathway and 
subsequently SRSF proteins. In addition, the fact that hTERT splicing pattern changed in 
favor of β-hTERT following the speculated activation of PI3K/AKT hints at a novel extra-
telomeric role of β-hTERT in survival/self-renewal of hESCs and supports the currently 
existing evidence for hTERT regulation by alternative splicing. Additionally, DOX-treated 
samples showed reduced splicing of α-β-hTERT in comparison to non-doxycycline treated 
groups (Fig. 3.2 E 4th and 5th columns). This relative reduction of α-β-hTERT transcript 
population may account for the shift of splicing toward β-hTERT transcript following 
doxycycline treatment. 
When doxycycline and hydrogen peroxide treatments were combined, strikingly, the 
proportion of β-hTERT transcript dropped down to the level of α+β+hTERT, while the α-β-
hTERT transcript remained low as seen in doxycycline-treatment only group. It is tempting 
to look for an explanation for this phenomenon through mitochondria since they are the 
known off-targets of doxycycline and are the central hub of intra-cellular free iron 
sequestration for the downstream heme and iron sulfur syntheses [221, 222]. In this context, 
the side effect of 2-day long doxycycline treatment (impairment of mitochondria) might have 
had a serendipitous effect of curtailing the free bivalent iron pool by the time H2O2 was 
introduced to the cells, reducing the generation of highly deleterious hydroxyl radicals. 
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Assuming the previously seen increase in β-hTERT splicing played a protective role (when 
doxycycline and hydrogen peroxide were applied singly), one may speculate that the 
cytotoxic effect of H2O2 might have been alleviated by mitochondrial impairment and AKT 
activation by doxycycline, leading to the overall reduction of intra-cellular stress and the 
resultant decrease in β-splicing. Future experiments that examine changes in intra-cellular 
ROS and AKT activation after DOX- and H2O2 treatments will be necessary to better explain 
this multi-faceted result. α-β-hTERT, despite the reduced β-splicing, remained unchanged, 
which suggest an independent role for α-β-hTERT isoform may exist. 
 
4.2 Transgenic HES2 line B6 and FL12 remain pluripotent following 
doxycycline and H2O2 treatment. 
For delineating TERT isoform function and to enable reliable detection of hTERT 
transgenic proteins, multiple transgenic HES2 lines were clonally established for DOX-
inducible overexpression of 3xFLAG-tagged β-hTERT and FL-hTERT transgenes. Four 
clonal cell lines established from HES2 β-hTERT (B2, B3, B6, B7) and HES2 FL-hTERT 
(FL7, FL9, FL10, FL12) were randomly chosen and analyzed for FLAG-tagged protein 
expression (appendix A3: Fig. 3.1). Based on preliminary results of 3xFLAG-hTERT 
transgene induction 12-hours post doxycycline, clonal cell line selection was further 
narrowed down to the least expressive β-clone HES2 B3, the most expressive HES2 B6, a 
FL-clone (FL9) with similar level of protein induction as B6 HES2, and the most expressive 
FL-clone HES2 FL12. The level of transgene induction in the selected clones was re-
examined by RT-qPCR using transgene-specific primers (n=1; I focused more on the protein 
because the goal of my study relies on the protein stability/expression rather than the 
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transcript stability) and by Western blot (Fig. 3.3). In all clones, both 3xFLAG-β-hTERT and 
3xFLAG-FL-hTERT expression peaked after 6 hour of doxycycline treatment and remained 
relatively unchanged over the 3 day-long doxycycline time course.  
Interestingly, the steady-state protein level of 3xFLAG-β-hTERT was significantly 
lower (approximately by 7-fold) than that of 3xFLAG-FL-hTERT (Fig. 3.3 C) regardless of 
the duration of doxycycline. This can arise from multiple factors including transcriptional 
activity at the promoter site of the recombinant gene, the stability of 3xFLAG-β-hTERT 
transcript, and protein degradation.  
The low protein expression of 3xFLAG-β-hTERT may result from diminished 
transcription of the transgene. 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT expression 
cassettes utilize identical promoter (pCAG), transactivator (TA), activator (DOX), and 
transactivator responsive element (TRE) (Fig. 2.1). Therefore, the differences in 
transcriptional activity of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT would depend on the 
site of and the multiplicity of transgene integration.  
In my preliminary characterization of transgenic transcript level by RT-qPCR (Fig. 
3.3 A, n = 1), I observed that 3xFLAG-β-hTERT transcripts slowly decrease over 3 days of 
doxycycline treatment in both HES2 B3 and B6, despite daily renewal of doxycycline in the 
growth media. Previously, it was shown that the NMD activity on β-hTERT transcript can 
vary in different cell types [102]. Greater than 90% depletion of UPF1 (core component of 
NMD machinery) resulted in 10-fold increase in β-hTERT transcript in UM-UC-3 cell line 
(bladder cancer), an indication that β-hTERT transcript can be targeted by NMD. Conversely, 
β-hTERT transcript in BT-549 cells (breast cancer; normally expresses high level of β-
hTERT) did not change significantly with the knockdown of UPF1, suggesting β-hTERT 
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transcript can escape NMD pathway depending on the cell type. Therefore, it would be 
interesting to perform a similar experiment to test the NMD sensitivity of β-hTERT transcript 
in hESC.  
The steady-state protein abundance of 3xFLAG-β-hTERT (B6) was consistently ~5-
fold less than that of 3xFLAG-FL-hTERT (FL12) at all doxycycline treatment times (Fig. 3.3 
C), whereas 3xFLAG-β-hTERT is only ~2-fold less than 3xFLAG-FL-hTERT at transcript 
level (Fig. 3.3 A). Adding to this, the steady-state transcript of 3xFLAG-FL-hTERT in FL9 
clone was ~3 times less than 3xFLAG-β-hTERT (B6), yet the protein abundance was ~3 
times higher at all doxycycline durations (Figure. 3.3 A and C). Listerman et al. and our lab 
previously confirmed the translational competency of β-hTERT transcript [100, 186] and α-
β-hTERT transcript [184] by polysome profiling. Collectively, these findings point to the 
possibility that 3xFLAG-β-hTERT protein has higher propensity to degrade than 3xFLAG-
FL-hTERT.  FL-hTERT is known to degrade by ubiquitination pathway [131– 133], but little 
is known about the protein degradation of β-hTERT. β-hTERT lacks a large portion of the C-
terminal end (Fig. 1.1 B), which is necessary for MKRN1-mediated ubiquitination/ 
degradation of hTERT[129]. Therefore, if 3xFLAG-β-hTERT is indeed degrading via 
ubiquitination, CHIP [130] or Hdm2 [131] may be at the focus of such regulation (see section 
1.2.4).  
I decided to work with the most expressive clones HES2 B6 and HES2 FL12 for the 
robustness of potential downstream effects and to adequately compare functional differences 
between overexpression of the two TERT isoform transgenes in hESCs. For the treatment 
time of doxycycline, I settled with 2 days of transgene induction by doxycycline for both B6 
and FL12 clones for maximum transgene expression (Fig. 3.3 A).  
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In the light of discoveries highlighting the importance of hTERT [185] and telomere 
maintenance [224-228], I performed immunofluorescence microscopy to assess the effect of 
TERT isoform transgene expression on the pluripotent status of the selected clones. Both 
HES2 B6 (Fig. 3.4) and HES2 FL12 (Fig. 3.5) stained positively for OCT4/SSEA-4, and 
negatively for SSEA-1, indicating their pluripotent state under normal culture conditions (2% 
oxygen, no H2O2 or doxycycline added). Following doxycycline (1μg/ml for 2 days) and/or 
H2O2 treatment (100μM for 4 hours), the cells stained in the same pattern and apparent 
intensity, suggesting, at least at the visible level, that pluripotency was not altered by the cell 
treatments (Fig. 3.4 and Fig. 3.5). This supports a previous study in mESC which showed 
that short-term treatment of H2O2 (150μM for 2 hours) did not affect the expression of 
pluripotency marker genes Oct4, Sox2, and Nanog [207]. However, no quantification was 
performed on the immunofluorescence intensities so it is possible that the pluripotency 
markers were changing over the course of cell treatments. Many cells were non-adherent and 
round in morphology (data not shown) by the end of 4-hour H2O2 treatment, which suggests 
the cells were responding to the acute oxidative stress by switching on the apoptotic pathway 
rather than by differentiating (loss of pluripotency). In support of this, Guo et al. 
demonstrated that mESCs, despite their increased resistance to senescence by oxidative 
stress, undergo apoptosis when treated with H2O2 at dose higher than 150 μM for 24 hours 
[207]. In the same study, a significant portion of mESCs treated with 150μM H2O2 for 3 
hours lost their ability to adhere to the surface of culture dish, and failed to recover when 
resuspended in fresh culture medium. This closely resembles my observation with H2O2-
treated hESC, and likely signifies a pre-apoptotic event that ultimately contributes to H2O2-
induced cell cycle arrest and apoptosis. 
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4.3 3xFLAG-hTERT in HES2 B6 and HES2 FL12 bind TERC and RMRP. 
To show the competency of the 3xFLAG-tagged-hTERT species in carrying out the 
known functions of non-tagged versions of hTERT, I tested their RNA-binding ability (Fig. 
3.6 and 3.7) and telomerase activity levels (Fig. 3.8) of the FLAG-tagged hTERT isoforms in 
HES2 hESCs. In FLAG-RIP experiments for TERC-binding, the amount of TERC recovered 
was significantly higher when doxycycline was added for both HES2 B6 and HES2 FL12 
(Fig. 3.7 B and C, respectively), but not for parental HES2 cells. The insignificant change 
observed with parental HES2 demonstrates that the significant differences observed in HES2 
B6 and HES2 FL12 were not due to a side-effect of doxycycline and/or because of 
nonspecific binding of TERC to the FLAG-antibody-conjugated beads. Together, the 
experiment confirms that both 3xFlag-tagged β-hTERT and FL-hTERT transgenic proteins 
can bind TERC in vitro. In a side-by-side comparison (Fig. 3.7 A), the fold-recovery of 
TERC was significantly higher for 3xFLAG-FL-hTERT (~60-fold increase) than for 
3xFLAG-β-hTERT (~10-fold increase). Interestingly, a similar RIP experiment by Listerman 
et al. [102] confirmed Flag-tagged β-hTERT bound to TERC. In stark resemblance with my 
results, Flag-tagged FL-hTERT co-immunoprecipitated only a 3-fold higher amount of 
TERC than Flag-tagged β-hTERT. It is tempting to conclude that FL-hTERT has greater 
affinity for TERC than β-hTERT. However, making any conclusions on the affinity would be 
inappropriate for a few reasons. First, my data for DOX-induced recombinant protein 
expression showed that the steady-state abundance of 3xFLAG-FL-hTERT was significantly 
higher than that of 3xFLAG-β-hTERT by approximately 5-fold (Fig. 3.3, see section 4.2). 
This disparity between the two cell lines can also lead to similar reduction in TERC-recovery 
by 3xFLAG-β-hTERT. Second, there is no way of knowing whether FLAG-hTERT proteins 
were bound to the immunoprecipitation beads to saturating capacity or not. In other words, if 
87 
 
 
 
the same volume (30μl packed volume) of anti-FLAG beads were binding 3xFLAG-FL-
hTERT to saturation, but not 3xFLAG-β-hTERT (possibly because of significantly low 
steady-state protein abundance of 3xFLAG-β-hTERT; see the beginning part of this section), 
no proper comparison can be made between 3xFLAG-FL-hTERT and 3xFLAG-β-hTERT 
since the amount of immunoprecipitated 3xFLAG-hTERT species differs. Thirdly, the fact 
hTERT can form dimers adds another layer of complexity. As shown in Fig. 1.1, β-hTERT 
lacks one of two oligomerization domains. If 3xFLAG-β-hTERT is less likely to self-
dimerize than 3xFLAG-FL-hTERT in-vitro, it is possible that the same amount of saturated 
anti-FLAG-beads were pulling down different amount of 3xFLAG-β-hTERT and 3xFLAG-
FL-hTERT. Further investigation is required to clarify this. 
RMRP is another RNA partner of hTERT. The domain for RMRP-binding on the 
protein is currently unknown [181]. I performed the identical RIP experiment as above to 
estimate the recombinant hTERTs’ ability to bind RMRP. As expected, no difference was 
seen amongst HES2 control group samples (Fig. 3.7 D). Similarly, RMRP recovery in HES 
B6 hESCs treated with doxycycline was not statistically different from its non-DOX-treated 
counterpart. The inherently low expression level of 3xFLAG-β-hTERT of HES2 B6 clone 
may have contributed to the low RMRP yield in DOX-treated group (Fig. 3.3, see section 
4.1). However, considering the identical doxycycline treatment (thus, presumably the same 
level of 3xFLAG-β-hTERT protein expression) used for TERC-RIP resulted in significant 
TERC recovery (Fig. 3.6 B), the low protein expression by HES2 B6 may not be the limiting 
factor. This points to the possibility that β-hTERT has impaired RMRP binding. Importantly, 
HES2 control group samples (Fig. 3.7D) and HES2 B6 samples (Fig. 3.7 B) precipitated 
comparable amount of RMRP, which suggests a substantial amount of RMRP might have 
been bound to the RIP beads non-specifically. The hypothesized non-specific precipitation 
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could have led to false positive reading of RMRP in non-DOX-treated samples, masking the 
truly immunoprecipitated (by 3xFLAG-β-hTERT) RMRP in DOX-treated HES2 B6. In 
support of a previous study by Maida et al. [164], I observed ~5-fold increase in RMRP 
recovery upon the addition of doxycycline to HES2 FL12, indicating the interaction of 
3xFLAG-FL-hTERT with RMRP (Fig. 3.7 C). In a side by side comparison of 3xFLAG-β-
hTERT and 3xFLAG-FL-hTERT (Fig. 3.7 A), 3xFLAG-FL-hTERT co-precipitated with 
approximately 2-fold more RMRP than 3xFLAG-β-hTERT. However, as discussed above, 
more optimization and redesigning of the experiment is necessary to compare binding 
affinities of RNA components between TERT isoforms.  
 
4.4 The effect of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT on the telomerase 
activity in HES2 B6 and HES2 FL12. 
 The effect of overexpressing 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT on 
telomerase activity in hESCs was investigated (Fig. 3.8). hESCs express endogenous 
telomerase reverse transcriptase (TERT) and exhibit high telomerase activity [184]. β-hTERT 
can act as a dominant negative inhibitor of telomerase activity by sequestering TERC [102]. 
It was proposed by the same study that this mode of inhibition is effective only when TERC 
is the limiting factor for telomerase activity. Potential side-effects of doxycycline on 
endogenous telomerase activity in non-transgenic HES2 was first tested. I demonstrated that 
doxycycline had no effect on endogenous telomerase activity levels since no significant 
difference in the activity was observed with doxycycline treatment compared to non-treated 
controls hESCs (Fig. 3.8 B first bar plot).  
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As expected, overexpression of 3xFLAG-β-hTERT led to significantly reduced levels 
of telomerase activity (Fig. 3.8 B second bar plot). This inhibition could result from several 
reasons. As previously suggested, the available pool of free TERC transcripts may be in 
limiting supply in hESCs and reduced by binding to catalytically inactive 3xFLAG-β-
hTERT, decreasing the number of active telomerase RNP complexes [102]. Although there is 
no confirmation on the formation of heterodimeric β-hTERT/FL-hTERT to date, such 
dimerization seems plausible given β-hTERT retains oligomerization domain for interaction 
with another hTERT protein [188]. Hence, one can speculate that the heterodimerization of 
3xFLAG-β-hTERT with the endogenous FL-hTERT may have caused an inactivation of the 
complex, which could additionally account for the observed inhibition of telomerase activity. 
Based on previous studies that showed TERC is in excess for telomerase complex 
formation in human immortalized cells [82, 226], I had anticipated that overexpressing 
3xFLAG-FL-hTERT would lead to increased total telomerase activity. Surprisingly, the 
overexpression of 3xFLAG-FL-hTERT did not significantly increase telomerase activity 
levels (Fig. 3.8 B third bar plot). To seek an explanation for this unexpected outcome, I 
stepped back and examined what was happening to the total hTERT (endogenous and 
transgenic) population at the transcript level (Fig. 3.9) by TaqMan qPCR (Fig. 2.1 B). Upon 
adding doxycycline to HES2 FL12, not only did the transcript abundance of α+β+hTERT 
increased by ~500 fold, those containing β- transcript species (β- and α-β-hTERT) also 
increased greatly by ~300 fold (Fig. 3.9 A). The transgenic DNA sequence for 3xFLAG-FL-
hTERT directly codes for the processed TERT mRNA species and does not include introns 
which are required for the alternatively splicing of β-hTERT [102]. This suggests that the 
observed increase in β-hTERT- and α-β-hTERT transcripts is due to the increased β-splicing 
of endogenous hTERT pre-mRNA. Moreover, doxycycline is unlikely a part of this as I had 
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seen no such tremendous increase in β-splicing in DOX-treated non-transgenic HES2 (Fig. 
3.2 C and E). This is very interesting result which demonstrates the cell’s ability to respond 
to ectopic expression of 3xFLAG-FL-hTERT. In other words, a feedback mechanism may 
exist in hESCs to sense the aberrant increase in α+β+hTERT transcript abundance and/or 
telomerase activity levels (canonical and/or non-canonical) of FL-hTERT and to 
downregulate it by switching to β-favoring splicing. In support of this, similar hTERT 
regulation by alternative splicing had been reported previously [79, 80, 110] (see section 
1.2.2). Thus, the significant increase in non-catalytic hTERT transcripts (β-hTERT and α-β-
hTERT) due to DOX-induced 3xFLAG-hTERT overexpression may be attributed to my 
failure to observe an increase in telomerase activity within this transgenic cell line. Notably, 
DOX-treatment in HES2 B6 only induced β-hTERT (~1000-fold induction) and α-β-hTERT 
(~200-fold induction). Since α-deletion is mediated by an alternative splice acceptor within 
exon 6 (therefore present in the 3xFLAG-β-hTERT transgene), The increase in α-β-hTERT 
transcript level may result from an additional α-deletion on the DOX-induced 3xFLAG- β-
hTERT transcript.  
The N-terminal end of hTERT is essential for telomerase activity as it contains an 
anchor site (TEN domain) to stabilize telomeric DNA-to-hTERT interaction [226], and TEN 
domain mutations are known to cause defective telomere maintenance in vivo [227]. 
Therefore, one may speculate that the N-terminal 3xFLAG could potentially disrupt this 
particular function of the TEN domain, leading to the failure of 3xFLAG-FL-hTERT to 
remain bound to the telomere-like DNA substrate in telomerase activity assay. However, 
several previous reports demonstrated unobstructed telomerase activity by N-terminal 
3xFLAG-tagged hTERT, suggesting that N-terminal 3xFLAG-tagging does not affect the 
telomerase activity in-vitro [71, 231, 232]. 
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4.5 The intra-cellular localization of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT 
in hESCs treated with H2O2-induced oxidative stress. 
 Several studies previously reported mitochondrial localization of FL-hTERT [187, 
189, 203, 208, 214] and β-hTERT [149] under oxidative stress. We previously shown that 
hTERT was more extra-nuclear localized in hESCs cultured under 21% oxygen conditions 
compared to the prominently nuclear TERT observed in cells cultured in 2% oxygen [184]. 
Western blot of sub-cellular fractions and immunofluorescence microscopy were used in this 
study to determine the intra-cellular localization of 3xFLAG-β-hTERT and 3xFLAG-FL-
hTERT when cells were treated with the characterized dose and duration of H2O2. 
 The amount of 3xFLAG-β-hTERT in mitochondrial and nuclear fractions did not 
change significantly over the time course of hydrogen peroxide treatment (Fig. 3.10 A and 
B). Similarly, no change in 3xFLAG-FL-hTERT was observed with H2O2 treatment in either 
fractions (Fig. 3.11 A and B). An independent set of the identical experiment was conducted 
with prohibitin as mitochondrial marker protein (for normalization of mitochondrial protein; 
appendix A4: Fig. 3.2). It showed similar results to when VDAC was used as the 
mitochondrial fractionation and loading control. Importantly, the fractionation quality (as 
determined by the presence of mitochondrial/nuclear markers in fractions) was rather 
inconsistent between experimental replicates (Fig. 3.10 and Fig. 3.11; data not shown), 
leading to highly variable results (Fig. 3.10, Fig. 3.11; appendix A4: Fig. 3.2; see error bars). 
hESCs exhibit high nuclear-to-cytoplasm ratio [230], and mitochondria of hESC are located 
in close proximity with the nuclei [230, 231]. Such intrinsic cell characteristics make clean 
separation of the two organelles very difficult [232– 234], a task I could not fully overcome.  
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 As an alternative method to fractionation, immunofluorescence imaging was 
performed on fixed HES2 B6 and HES2 B12 cells after H2O2 treatment (Fig. 3.12). There 
was no apparent co-localization of either 3xFLAG-β-hTERT or 3xFLAG-FL-hTERT with 
mitochondria after H2O2 treatments. 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT were 
predominantly nuclear with only minute amount of 3xFLAG-hTERT localized to the 
cytoplasmic space. Our lab previously observed extra-nuclear localization of endogenous 
hTERT in H9 line under chronic exposure to 21% O2 for 5 days [184]. However, I failed to 
observed this in HES2 FL12 that had been exposed to 21% O2 for 3 days (appendix A5: Fig. 
3.3). there were some nuclei with 3xFLAG-hTERT located very close to the nuclear 
boundary (Fig 3.12 indicated by white arrow). I believed this intra-nuclear localization 
pattern might be the influence of H2O2-induced oxidative stress, and performed a blinded 
cell-count analysis on immunofluorescence microscopy images (Fig. 2.2 and Fig. 3.13). 
Unfortunately, the analysis revealed no significant effect of hydrogen peroxide on 3xFLAG-
β-hTERT and 3xFLAG-FL-hTERT localization within hESCs.  
 The observed localization pattern of 3xFLAG-FL-hTERT is particularly puzzling as it 
directly contradicts previous studies that demonstrated extra-nulcear-[184] and mitochondrial 
[185, 186, 197, 240] localization of FL-hTERT under H2O2-induced oxidative stress. These 
studies employed wide range of dose and duration of oxygen tension/hydrogen peroxide 
[186, 187, 197], or no oxidative stress at all [175]. The dose of hydrogen peroxide used in 
these studies vary from 200μM to 500μM, and the duration of H2O2 treatment ranged from 3 
hours to 5 days. The different cell types used in the studies (NHF, HeLa [175], fetal human 
lung fibroblast cell MRC5 [195], breast cancer cell MCF7 [183]) add extra layer of 
complexity to this, making it nearly impossible to predict the right dose and time window of 
H2O2 to use in hESC for inducing mitochondrial localization of hTERT. In my preliminary 
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immunofluorescence experiments with earlier (15 minutes, 30 minutes, 1 hour) and longer 
duration (4 hours, at which point the cells were apoptotic; see last paragraph of section 4.1) 
of 100 μM H2O2 treatment (data not shown), 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT 
remained mostly nuclear. Based on this, it is likely that I am targeting right (inducing cell 
stress) dose and sufficiently wide time window of H2O2 treatment. Considering the hTERT 
investigated in previous studies were either endogenously expressed protein  [195] or tagged 
with relatively small tag such as myc (1.2 kDa) [186, 240], the large size of 3xFLAG tag (2.8 
kDa) used in my study may be physically hindering the trans-membrane translocation of 
3xFLAG-β-hTERT and 3xFLAG-FL-hTERT. However, EGFP (32.7 kDa)-tagged hTERT 
used by Santos et al.[175] was able to cross both nuclear and mitochondrial membrane, 
precluding this possibility. Importantly, the mitochondrial targeting sequence (MTS) of 
hTERT lies at the N-terminal end. Thus, the location (N-terminal vs C-terminal) and the 
amino acid (a.a.) constituents of the tagging can greatly influence the proper function of 
MTS. Mitochondrial targeting sequences, as outlined in a review by Walter Neupert [237], 
are generally 20-60 amino acid long, rich in positively charged a.a., and have the tendency to 
fold into amphiphilic α-helices. 3xFLAG is particularly enriched in negatively charged 
aspartate residues [238]. The negative charge on N-terminally tagged 3xFLAG may negate 
the positive charge on MTS, ultimately disabling MTS and abolishing mitochondrial 
localization. However, this does not fully explain my failure to observe not only the 
mitochondrial translocation but also the extra-nuclear localization of 3xFLAG-hTERT. 
Phosphorylation by Src at tyrosine 707 is required for nuclear export of hTERT by 
CRM1/Ran interaction near the C-terminal of hTERT [142] (Fig 1.2 B). β-hTERT does not 
have this C-terminal region due to PTC-mediated truncation, and it is possible that 3xFLAG-
β-hTERT was trapped inside nuclei because of the impaired CRM1/Ran-mediated nuclear 
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export. Under the assumption that the two ends of the protein come into close proximity in 
the native state, the N-terminal 3xFLAG-tag may block CRM1-hTERT interaction through 
steric hindrance, leading to nuclear trapping of 3xFLAG-FL-hTERT. For clarification, it 
would be necessary to investigate whether Y707 phosphorylation of FLAG-tagged TERT 
isoforms occurs upon H2O2 treatment in hESCs.  
 
4.6 Investigation of the effect of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT on 
mitochondria function in hESCs. 
 Ahmed et al. [195] demonstrated that ectopic expression of FL-hTERT in human fetal 
lung fibroblast cells results in increased mitochondria membrane potential and decreased 
mitochondria DNA content. Of note, the study did not consider whether mitochondrial 
localization of FL-hTERT was required for such changes. In my study, the potential 
mitochondrial changes in hESC after overexpressing 3xFLAG-β-hTERT and 3xFLAG-FL-
hTERT were assessed.  
 Mitochondria membrane potential (MMP) was estimated by FL2 (fluorescence signal 
from J-aggregate, indicator of high membrane potential) to FL1 (fluorescence signal from 
JC-1 monomer, indicator of low membrane potential) ratio using flow cytometry (see section 
2.5.1; Fig. 3.14 and 3.15). To account for the possibility of doxycycline side effect, DOX-
treated non-transgenic HES2 was include in the experiment. The fold change in 
mitochondrial membrane potential (MMP) with DOX-treated HES2 F12 and HES2 B6 did 
not differ from DOX-treated non-transgenic HES2 control (Fig. 3.15). My failure to observe 
increase in MMP in DOX-treated HES2 FL12 may owe to the fact that DOX-induction in 
this cell line increases not only the 3xFLAG-FL-hTERT expression but also other hTERT 
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isoforms containing β-deletion (see section 4.2 of discussion). Certain mitochondrial roles of 
hTERT, such as DNA damage-amplifying [235] and mitochondrial ROS-reducing effects 
[173] requires the catalytically active form of  hTERT. To date, there is no concrete evidence 
indicating that MMP-enhancing role of FL-hTERT strictly requires its presence in 
mitochondria, a large body of MMP-determining factors are nuclearly transcribed [65, 243].  
control  In this context, sufficiently expressed β-hTERT, a catalytically inactive form, could 
mask, and even inhibit the MMP-enhancing role of FL-hTERT from nuclei (recall 3xFLAG- 
β-hTERT remained in nuclei; see section 4.5). The fold change in MMP of DOX-treated 
HES2 B6 decreased slightly in comparison to that of HES2 control, but was not statistically 
significant (p = 0.0635, paired t-test). Considering the low level of DOX-induction of 
3xFLAG-β-hTERT in HES2 B6 (see section 4.2), I believed that a significant change in 
MMP may be observed if 3xFLAG-β-hTERT can be overexpressed more robustly.  
 The effect of overexpressed 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT on 
mitochondrial DNA (mtDNA) copy number was examined by qPCR. I confirm a side-effect 
of doxycycline by showing that mtDNA content decreases by ~20% in non-transgenic HES2 
after doxycycline treatment. (Fig. 3.16 A). As previously mentioned, several past studies 
have shown that tetracycline family drugs can impair eukaryotic mitochondrial function by 
inhibiting mitochondrial ribosome [212 - 215], which suggests doxycycline may be hindering 
the mtDNA synthesis process. Interestingly, the reduction in mtDNA content was not 
detected when 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT were overexpressed with 
doxycycline (Fig. 3.16 B and C). It was proposed that mtDNA synthesis involves priming of 
a nascent RNA from light strand promoter (LSP) [240] by a RNase formed between 
mitochondrial RNA processing endoribonuclease (RNase MRP) and RMRP (RNA 
component of the mitochondrial RNA-processing endoribonuclease) [241]. Studies by Maida 
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et al. [178, 185] and my earlier results (Fig. 3.7) demonstrated the interaction of RMRP with 
FL-hTERT and β-hTERT. In the context of successful mitochondrial localization of RMRP-
bound 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT, the available pool of RMRP in 
mitochondria may increase, promoting mtDNA synthesis. However, my previous results 
indicate no mitochondrial localization of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT in 
hESCs. Therefore, an intricate interplay between hTERT and RNase MRP (also known to be 
both nuclear and mitochondrial [242]) may exist to regulate mitochondria DNA synthesis 
from the nucleus.  
 To further investigate the regulation of mitochondria by nuclear 3xFLAG-β-hTERT 
and 3xFLAG-FL-hTERT, the expression of genes involved in mitochondria biogenesis (Fig. 
3.17) and function (Fig. 3.18) was measured by RT-qPCR. PGC1 family proteins (PGC1A, 
PGC1B, PRC) are well known regulators of mitochondria biogenesis [243]. PGC1B, together 
with NRF1 (nuclear respiratory factor 1), stimulates the expression of target genes including 
regulators of mitochondria DNA replication (TFAM and POLG) [244] and mitochondrial 
transcription (TFAM and TFB1M) [240]. In support of the results from my mtDNA copy 
number experiment, the overexpression of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT did 
not affect the transcript abundance of any of the mitochondria biogenesis regulators (Fig. 
3.17). Moreover, doxycycline treatment did not change the transcript abundance in HES2 
(non-transgenic hESCs) (Fig. 3.17). This result indicates that DOX-induced reduction in 
mtDNA copy number observed earlier (Fig. 3.16) is not mediated by changes in nuclear 
transcribed genes, but more likely through direct intervention of doxycycline with the 
mitochondria. In terms of function, mitochondria of hPSC contain high levels of Mn-SOD2 
(antioxidant enzyme)[66] and UCP2 (uncoupler protein)[245]. The steady-state transcript 
level of these genes also did not change with doxycycline treatment in any of the HES2 cell 
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lines (Fig. 3.18). Notably, UCP2 transcript level in all HES2 cells lines was much higher than 
other genes measured simultaneously, which supports the notion that HES2 is pluripotent cell 
with metabolic reliance on glycolysis (through down-regulation of OXPHOS through 
removal of carbon intermediates in the mitochondria matrix) [246]. 
 
4.7 The effect of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT on cell survival of 
HES2 lines under H2O2-induced oxidative stress. 
 H2O2 exposure at a high concentration can lead to generation of highly deleterious 
hydroxyl radicals and damage various cell components including lipids, proteins, and DNA. I 
conducted flow-cytometry experiments to measure cell survival/death in the various HES2 
hESC lines under H2O2-induced oxidative stress. 
 First, the potential side effect of doxycycline on cell viability (Annexin V-FITC-/7-
AAD-), apoptosis (Annexin V-FITC+/7-AAD-), and cell death (7-AAD+) was assessed by 
flow cytometry in nontransgenic HES2 cells (Fig. 3.20-22 A). Our results show that 
doxycycline has no effect on cell survival under H2O2-induced cell stress (Fig. 3.20-22 A).  
When 3xFLAG-β-hTERT overexpression was induced via doxycycline, % cell 
viability decreased (Fig. 3.20 B) while the apoptotic population increased in HES2 B6 (Fig. 
3.21 B). However, the dead cell population remained unchanged (Fig. 3.22 B). On the other 
hand, when 3xFLAG-FL-hTERT was overexpressed via DOX, the viable population 
dramatically increased (Fig. 3.20 C) while the apoptotic population decreased (Fig. 3.21 C). 
In cancer research, there have been several reports demonstrating anti-apoptotic role of 
hTERT against chemotherapeutic drugs [251-254]. In research conducted by Cao et al. [248], 
a short-term knock down of endogenous hTERT (measurements were taken 24 hours post 
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antisense RNA-mediated knock down) in breast cancer cells resulted in increased apoptosis 
without change in telomere length. The hTERT-depletion-mediated apoptosis was overcome 
by overexpression of catalytically active and inactive hTERT, suggesting anti-
apoptotic/extra-telomeric role of hTERT and its non-catalytic versions. In my study, 
however, the cell survival of H2O2-treated hESC is enhanced by 3xFLAG-FL-hTERT, not by 
3xFLAG-β-hTERT. It is highly possible that 3xFLAG-β-hTERT and hTERT mutant used by 
Cao et al. behave differently due to their structural differences. Moreover, the types of cells 
and stress used in the studies are completely different, which can also contribute to the 
disparate outcome. The pro-survival role of hTERT is mediated through modulation of 
Bcl2/Bax and the resultant mitochondria-dependent apoptosis pathway[251, 253]. 
Importantly, the inhibition of Bax-dependent apoptosis signaling was simultaneous with 
mitochondrial localization of hTERT. Therefore, my failure to observe mitochondrial 
localization of 3xFLAG-hTERT suggests that the augmented cell viability following 
doxycycline treatment in HES2 FL12 is possibly independent of Bax pathway. There has 
been several reports of the protective role of hTERT on mitochondrial [188, 225] and 
nuclear[183] DNA. All three studies proposed that DNA-protection by hTERT is mediated 
through reduction of mitochondrial generated ROS. hESCs have minimally active OXPHOS 
activity, and have lower mitochondrial ROS than its differentiated progeny [66]. Therefore, it 
is likely that the cells were exposed to an exogenous source of ROS (H2O2) that is far more 
damaging than the endogenous ROS generated by mitochondria of hESC. It is speculated that 
the anti- and pro-survival effect exhibited by 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT, 
respectively, would result from fundamental changes in anti-oxidant/DNA-repair 
mechanisms.  
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 In addition, we show that DOX-induction in FL12 slightly increased dead cell 
population by ~2.5% (Fig. 3.22 C). At first glance, this may be puzzling because we 
demonstrated in the same experiment that DOX treatment in FL12 led to increase viability 
and decreased apoptosis. However, knowing that DOX-treated FL12 accompanies a 
significant increase in β-hTERT and α-β-hTERT transcript (Fig. 3.9 A), one can speculate 
that the molecular interactions between DOX-induced 3xFLAG-FL-hTERT and endogenous 
β-hTERT isoforms may lead to increased cell death.  
Considering 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT are predominantly nuclear 
under the treatment conditions (Fig. 3.12), I believe that the effect of 3xFLAG-β-hTERT and 
3xFLAG-FL-hTERT on cell survivability under oxidative stress is likely mediated through 
its nuclear regulation, not through mitochondria. NF-kB is a key regulator of pluripotent state 
of hESC (see 1.3.2) and executes diverse cell functions including survival and apoptosis. 
Importantly, the nuclear translocation of p65 (one of five transcription factors in NF-kB 
signaling) is facilitated by its direct molecular interaction with hTERT and vice versa [255, 
256]. In the light of recent discovery demonstrating H2O2-activated p65 and its nuclear 
translocation [253], it is highly likely that NF-kB plays a major role in the nuclear 
localization/retention of 3xFLAG-β-hTERT and 3xFLAG-FL-hTERT following H2O2 
treatment, and their transcriptional activity in the nucleus to modulate cell survival under 
oxidative stress. For a future experiment, the molecular interaction between p65 and   
3xFLAG-β-hTERT/ 3xFLAG-FL-hTERT should be tested using anti-FLAG-
immunoprecipitation. 
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4.8 Concluding remarks and proposed future studies 
 hTERT remains a difficult protein to study due to its vastly diverse functions in 
different organelles, and for the poorly characterized mechanisms of its alternative splicing 
and isoforms. In this thesis, I show that hTERT transcript is alternatively spliced into 
isoforms carrying both α-deletion and β-deletion (α-β-), an α-deletion (α-), a β-deletion (β-), 
and neither deletion (α+β+) in hESC. The alternative splicing of hTERT pre-mRNA was 
affected significantly by both doxycycline and H2O2 treatments. It would be worthwhile to 
examine the physiological significance of the altered splicing in a future study. Using 
3xFLAG-tagged recombinant hTERT proteins, I showed that 3xFLAG-β-hTERT 
overexpression inhibited the endogenous telomerase activity. The overexpression of 
3xFLAG-FL-hTERT, on the other hand, did not change the telomerase activity, which I tried 
to explain through an aberrant increase in endogenous β-containing hTERT transcripts 
following DOX-induction in FL12 cells. To delineate the differences in isoform-specific 
functions, a better-controlled method to overexpress hTERT isoforms should be devised. 
Importantly, I failed to observe any physical/functional association between the recombinant 
hTERT isoforms and mitochondria in hESCs. To validate this, future experiments should 
focus on investigating the phosphorylation status of hTERT and kinases involved in hTERT 
cross-membrane translocation. Additionally, differently tagged- (smaller tag size and C-
terminal location), or non-tagged hTERT isoforms should be considered. Lastly, I 
demonstrated the pro-survival role of FL-hTERT and the pro-apoptotic role of β-hTERT in 
hESCs under H2O2-induced stress. Based on my results, previous literature, and the 
known/observed side effects of doxycycline, I conclude that more extensive assessment on 
intra-cellular ROS and ROS-induced damage is required for an appropriate interpretation of 
the results. 
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 Despite the great amount of evidence pointing to the extra-telomeric roles of the 
general hTERT population, surprisingly little effort has been made to tease out the functional 
significance of different hTERT isoforms and the regulation of hTERT splicing. For better 
understanding of hTERT, more attention to developing better techniques and tools for the 
detection of all hTERT isoforms is required so that TERT isoform-specific functions can be 
elucidated. 
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Appendix: Supplemental Figures and Tables 
A1: Table 2.1 List of PCR primers 
Primer Target 
Sequence 
(Forward/Reverse) 
Reference 
Taqman α+β+ TCAAGGTGGATGTGACGGG/ 
GGACTTGCCCCTGATGCG 
[254] 
Taqman β- TCAAGGTGGATGTGACGGG/ 
GGCACTGGACGTAGGACGTG 
[254] 
Taqman α- CCTGAGCTGTACTTTGTCAAGGA/ 
GGACTTGCCCCTGATGCG 
[254] 
Taqman α-β- CCTGAGCTGTACTTTGTCAAGGA/ 
GGCACTGGACGTAGGACGTG 
[254] 
Taqman Probe [6FAM] 
CGTGTTCTGGGGTTTGATGATGCTGGCGA[6FAM] 
[254] 
β-GEO CCTGCTGATGAAGCAGAACA/ 
TTGGCTTCATCCACCACATA 
 
TERC CGCCTTCCACCGTTCATTCT/ 
GCTGACAGAGCCCAACTCTT 
 
RMRP AAAGTCCGCCAAGAAGCGTA/ 
CTGCCTGCGTAACTAGAGGG 
 
β-actin TCAAGATCATTGCTCCTCCTGAG/ 
ACATCTGCTGGAAGGTGGACA 
 
HPRT1 CCCTGGCGTCGTGATTAGTG/ 
TCGAGCAAGACGTTCAGTCC 
 
TS AATCCGTCGAGCAGAGTT [191] 
ACX GCGCGGCTTACCCTTACCCTTACCCTAACC [191] 
TSNT AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCG
AT 
[191] 
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NT ATCGCTTCTCGGCCTTTT [191] 
Mitochondrial 
tRNA 
CACCCAAGAACAGGGTTTGT/ 
TGGCCATGGGTATGTTGTTA 
[255] 
B2M CCAGCAGAGAATGGAAAGTCAA/ 
TCTCTCTCCATTCTTCAGTAAGTC 
[255] 
POLG CATTGGACATCCAGATGCTG/ 
CCTGATATGAGCTCGGTCAA 
 
PGC1B CCACATCCTACCCAACATCAAG/ 
CACAAGGCCGTTGACTTTTAGA 
 
NRF1 GGAGTGATGTCCGCACAGAA/ 
CGCTGTTAAGCGCCATAGTG 
 
TFAM TATCAAGATGCTTATAGGGC/ 
ACTCCTCAGCACCATATTCT 
 
TF1BM TCTGCAATGTTCGACACATC/ 
ACCTATATAAGAAGCTCCAC 
 
SOD2 GGGATTGATGTGTGGGAGCA/ 
TGACTAAGCAACATCAAGAAATGC 
 
UCP2 ACAAGACCATTGCCCGAGAG/ 
AGGAGGGCATGAACCCTTTG 
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A2: Table 2.2 List of antibodies and dyes 
Target Company Host Catalogue # 
3xFLAG Sigma Mouse Monoclonal F1084 
β-ACTIN Cell signaling Rabbit Monoclonal 5125S 
Histone H3 Cell signaling Rabbit Monoclonal 4499 
Prohibitin Abcam Mouse Monoclonal ab55618 
VDAC New England Biolabs Rabbit Monoclonal 4661S 
TOM20 Protein Technologies Rabbit Polyclonal 11802-1-AP 
Alexa Fluor 488 Abcam Goat ab150113 
Alexa Fluor 594 Abcam Goat ab150080 
MitoTracker  
CMX ROS 
ThermoFisher - M7512 
DAPI ThermoFisher - R37606 
JC-1 ThermoFisher  T3168 
Calcein AM eBioscience - 65-0853-39 
7-AAD eBioscience - 00-6993 
Annexin V-FITC ThermoFisher - A13199 
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A3: Fig. 3.1 The amount of 3xFLAG-hTERT in the respective HES2 clones after 6-
hours and 12- hours post doxycycline induction. 3xFLAG-hTERT isoform expression 
was induced via 1μg/ml doxycycline (6 and 12 hours) in HES2 transgenic clones grown 
under normoxia (21% O2). Cells were harvested and processed for Western blot. 
Membranes were probed for 3xFLAG-hTERT isoforms using M2 anti-FLAG mouse 
monoclonal antibodies (Sigma). The protein level of 3xFLAG-hTERT isoforms in each 
clone at each time point of doxycycline treatment was compared by Western blot & 
densitometry analysis. Clonal names are in forms of B# for 3xFLAG-β-hTERT-expressing 
lines, and FL# for 3xFLAG-FL-hTERT-expressing lines.  
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A4: Fig. 3.2 H2O2-induced oxidative stress and its effect on the cellular localization of 
3xFLAG-hTERT. Cells were grown under 2% O2 and were treated with 1μg/ml DOX for 
two days prior to harvest. 100μM H2O2 was applied at different times (30m, 1hr, 2hr) prior 
to harvest. Mitochondria- and Nuclei-enriched fractions were isolated by differential 
centrifugation. The amount of A) 3xFLAG-β-hTERT and B) 3xFLAG-FL-hTERT in 
mitochondrial (left side)/nuclear (right side) fractions was investigated by Western blot 
(data not shown)/densitometry analysis. Results were normalized to prohibitin and histone 
H3 for mitochondrial and nuclear fractions, respectively. Densitometry results of treatment 
groups are relative to H2O2 negative control n=3, error bar=±SEM. NS = non-significant. 
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A5: Fig. 3.3: The effect oxygen tension on the intra-cellular localization of 3xFLAG-
FL-hTERT in hESCs. Transgenic hESCs were grown under 21% O2 and 2% O2. HES2 
FL12 were treated with 1μg/ml DOX for two days prior to harvest. 100μM H2O2 was applied 
at different time points (15min, 30min, 45min, 1hr, 2hr prior to fixation). 
Immunofluorescence of 3xFLAG-FL-hTERT (green fluorescence), nuclei (DAPI; blue 
fluorescence), and mitochondria (TOM20; red) was visualized with a confocal microscope 
(Zeiss LSM 5 Duo Vario). Images were taken using 63X oil-immersion objective lens and 
x10 eyepiece lens. Scale bars = 20 µm. 
130 
 
 
 
Curriculum Vitae                                                                 Joohwan Kim 
 
 
 
Education 
2006 - 2012   B.Sc. (Honors) in Biochemistry at University of Guelph, Ontario, Canada 
(2 years spent as Republic of Korea Army in the duration of undergraduate             
studies) 
2013         Lab internship at an embryology laboratory  
Gyeongsang National University, Korea 
Jan 2014 -    M.Sc. student at University of Western Ontario,  
Department of Physiology and Pharmacology.   
 
Relevant Laboratory Skills 
 
 Mammalian Cell/Micro-organism culturing 
 Embryo culturing/manipulation 
 Basic lab techniques for molecular analysis (e.g. PCR, Immunoprecipitation, etc.) 
 
Publication 
 
J. H. Teichroeb, J. Kim, and D. H. Betts (2016), “The Role of Telomeres and Telomerase 
Reverse Transcriptase Isoforms in Pluripotency Induction and Maintenance,” RNA Biol., vol. 
6286, no. January, pp. 00–00,. 
 
 
 
 
 
131 
 
 
 
Research Experiences 
 
May 2012 – Aug 2012 |      Research Project as undergraduate student, department of 
molecular and cellular biology, University of Guelph (supervised 
by Dr. Jnanankur Bag) 
 Poly(A) binding proteins and the qualitative investigation of 
their interactions with translation regulators in HeLa. 
 
Relevant techniques: 
 Maintenance of cell culture (HeLa) 
 Western Blot 
 
Jul 2013 – Dec 2014 |         Research Project at Theriogenology Lab, College of Veterinary 
Medicine, Gyeongsang National University, South Korea 
(supervised by Dr. Gyu-Jin Rho) 
                       The effect of melatonin on proliferation/pluripotency of 
porcine mesenchymal stem cells (MSC):  
 
Relevant techniques: 
 Maintenance and directed differentiation of MSCs  
 
Jan 2014 – Current   |   M.Sc. Student, Physiology and Pharmacology, University of 
Western Ontario, (supervised by Dr. Dean H. Betts) 
                      FL- and β-variant of human telomerase reverse transcriptase 
in the regulation of mitochondria of human embryonic stem 
cell. 
 
Relevant techniques: 
 Maintenance of human embryonic stem cell 
 Immunofluorescence (Confocal microscopy) 
 Various types of PCR 
 RNA-immunoprecipitation 
 Cloning 
